<SEC-DOCUMENT>0001104659-20-072893.txt : 20200612
<SEC-HEADER>0001104659-20-072893.hdr.sgml : 20200612
<ACCEPTANCE-DATETIME>20200612160213
ACCESSION NUMBER:		0001104659-20-072893
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200612
DATE AS OF CHANGE:		20200612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MUSTANG BIO, INC.
		CENTRAL INDEX KEY:			0001680048
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473828760
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226175
		FILM NUMBER:		20960216

	BUSINESS ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		7816524507

	MAIL ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2022421d1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)<BR>
 &#8202;Registration Nos. 333-226175 and 333-233350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>PRELIMINARY PROSPECTUS SUPPLEMENT<BR>
To Prospectuses dated July 27, 2018 and September 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>10,769,231
shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2022421d1_42b5img001.jpg" ALT="" STYLE="height: 114pt; width: 173.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering
10,769,231 shares of our common stock. Our common stock is traded on The Nasdaq Global Market under the symbol
 &ldquo;MBIO.&rdquo; The last reported sale price of our common stock on June 9, 2020 was $4.26 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in these
securities involves a high degree of risk. Before buying shares of our common stock, you should carefully consider the risk factors
described in &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement and in the documents incorporated by
reference into this prospectus supplement and any free writing prospectus that we have authorized for use in connection with this
offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus supplement is accurate or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><B><I>Per Share</I></B> &nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><B><I>Total</I></B> &nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 74%; font-size: 10pt">Public offering price</TD>
<TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.25</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="width: 10%; font-size: 10pt; text-align: right">35,000,000</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">0.195<FONT STYLE="font-size: 10pt"></FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">2,100,000<FONT STYLE="font-size: 10pt"></FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Proceeds to us (before expenses)</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">3.055<FONT STYLE="font-size: 10pt"></FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">32,900,000<FONT STYLE="font-size: 10pt"></FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(1)</SUP> See the section entitled
 &ldquo;Underwriting&rdquo; beginning on page S-11 for a description of the compensation payable to the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted the
underwriters an option for a period of 30 days to purchase up to an additional 1,615,384 shares
of our common stock at the price per share set forth above. If the underwriters exercise the option in full, the total proceeds
to us, before expenses, will be approximately $40,250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters expect
to deliver the shares of common stock against payment on or about June 15,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>Sole
    Book-Running Manager</I></FONT><BR>
    <FONT STYLE="font-size: 18pt"><B>Cantor</B></FONT><BR>
    <BR>
    <I>Lead Manager</I><BR>
    <FONT STYLE="font-size: 16pt"><B>Oppenheimer &amp; Co.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this Prospectus Supplement is
June 11, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus Supplement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 45%"></TD><TD STYLE="width: 45%; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; width: 10%"><U>Page</U></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="width: 90%; text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_001">ABOUT THIS PROSPECTUS SUPPLEMENT</A></TD>
<TD STYLE="width: 10%; text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_001">S-1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_002">FORWARD-LOOKING STATEMENTS</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_002">S-2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_003">PROSPECTUS SUPPLEMENT SUMMARY</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_003">S-3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_004">THE OFFERING</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_004">S-5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_005">RISK FACTORS</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_005">S-6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_006">USE OF PROCEEDS</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_006">S-8</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_007">DIVIDEND POLICY</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_007">S-9</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_008">DILUTION</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_008">S-10</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_009">UNDERWRITING</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_009">S-11</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_010">LEGAL MATTERS</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_010">S-20</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_011">EXPERTS</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_011">S-20</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_012">WHERE YOU CAN FIND ADDITIONAL INFORMATION ABOUT US</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_012">S-21</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_013">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD>
<TD STYLE="text-align: right; padding-top: 2pt; padding-bottom: 0pt"><A HREF="#s_013">S-21</A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus (Registration No. 333-226175)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="#pro_01"><FONT STYLE="text-transform: uppercase">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 10%"><A HREF="#pro_01"><FONT STYLE="text-transform: uppercase">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#pro_03"><FONT STYLE="text-transform: uppercase">Important information About This Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_03"><FONT STYLE="text-transform: uppercase">2</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_04"><FONT STYLE="text-transform: uppercase">Description Of Capital Stock</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_04"><FONT STYLE="text-transform: uppercase">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#pro_05"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_05"><FONT STYLE="text-transform: uppercase">5</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_06"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_06"><FONT STYLE="text-transform: uppercase">6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#pro_07"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_07"><FONT STYLE="text-transform: uppercase">9</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_08"><FONT STYLE="text-transform: uppercase">Plan Of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_08"><FONT STYLE="text-transform: uppercase">10</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#pro_09"><FONT STYLE="text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_09"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_10"><FONT STYLE="text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_10"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#pro_11"><FONT STYLE="text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_11"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_12"><FONT STYLE="text-transform: uppercase">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_12"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">Prospectus (Registration No. 333-233350)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; text-transform: uppercase">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 10%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; text-transform: uppercase">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Important information About This Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt; text-transform: uppercase">2</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description Of Capital Stock</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">9</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Plan Of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">10</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_001"></A>ABOUT THIS
PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This document is in
two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stock and
also adds to and updates information contained in the accompanying prospectuses and the documents incorporated by reference in
this prospectus supplement and the accompanying prospectuses. The second part, the accompanying prospectuses, provides more general
information, some of which may not apply to this offering. Generally, when we refer to this prospectus supplement, we are referring
to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus
supplement and the information contained in the accompanying prospectuses or any document incorporated by reference that was filed
with the U.S. Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, you should rely on the
information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement
in another document having a later date &mdash; for example, a document incorporated by reference in the accompanying prospectuses
 &mdash; the statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further note that
the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor the
underwriters have authorized anyone to provide information different from that contained in this prospectus supplement and the
accompanying prospectuses, including any free writing prospectus that we have authorized for use in this offering. When you make
a decision about whether to invest in our common stock, you should not rely upon any information other than the information in
this prospectus supplement or the accompanying prospectuses, including any free writing prospectus that we have authorized for
use in this offering. Neither the delivery of this prospectus supplement or the accompanying prospectuses, including any free writing
prospectus that we have authorized for use in this offering, nor the sale of our common stock means that information contained
in this prospectus supplement and the accompanying prospectuses, including any free writing prospectus that we have authorized
for use in this offering, is correct after their respective dates. It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying prospectuses, including the information incorporated by reference
into this prospectus supplement and the accompanying prospectuses, and any free writing prospectus that we have authorized for
use in connection with this offering in making your investment decision. You should also read and consider the information in the
documents to which we have referred you in the sections entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference&rdquo; in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering to
sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the accompanying prospectuses and the offering of the common stock in certain jurisdictions may
be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectuses must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution
of this prospectus supplement and the accompanying prospectuses outside the United States. This prospectus supplement and the accompanying prospectuses do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy,
any securities offered by this prospectus supplement and the accompanying prospectuses by any person in any jurisdiction in which
it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in this prospectus supplement or the context otherwise requires, all references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo;
 &ldquo;the Company,&rdquo; and &ldquo;Mustang&rdquo; refer Mustang Bio, Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_002"></A>FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain matters discussed
in this prospectus supplement may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended,
or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown
risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different
from the future results, performance or achievements expressed or implied by such forward-looking statements. The words &ldquo;anticipate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo;
 &ldquo;project,&rdquo; &ldquo;intend&rdquo; and similar expressions are generally intended to identify forward-looking statements.
Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors,
including, without limitation, those discussed under the caption &ldquo;Risk Factors&rdquo; contained in this prospectus supplement,
the accompanying prospectuses, any applicable free writing prospectus and under similar heading in the other documents that are
incorporated by reference into this prospectus supplement. All written or oral forward-looking statements attributable to us are
expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited
to, statements about our:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations for increases or decreases in expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations for the clinical and pre-clinical development, manufacturing, regulatory approval,
and commercialization of our product candidates or any other products we may acquire or in-license;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our use of clinical research centers and other contractors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations for incurring capital expenditures to expand our research and development and manufacturing
capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations for generating revenue or becoming profitable on a sustained basis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations or ability to enter into marketing and other partnership agreements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations or ability to enter into product acquisition and in-licensing transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations or ability to build our own commercial infrastructure to manufacture, market and sell
our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance of our products by doctors, patients or payors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to compete against other companies and research institutions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to secure adequate protection for our intellectual property;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to attract and retain key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">availability of reimbursement for our products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">estimates of the sufficiency of our existing cash and cash equivalents and investments to finance
our operating requirements, including expectations regarding the value and liquidity of our investments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the volatility of our stock price;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expected losses; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expectations for future capital requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking
statements contained in this prospectus supplement reflect our views and assumptions only as of the date of this prospectus supplement,
respectively. Except as required by law, we assume no responsibility for updating any forward-looking statements. We qualify all
of our forward-looking statements by these cautionary statements. New risks and uncertainties arise from time to time, and it is
impossible for us to predict these events or how they may affect us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights information
contained elsewhere or incorporated by reference in this prospectus supplement, the accompanying prospectuses and in the documents
we incorporate by reference. This summary does not contain all of the information that you should consider before deciding to invest
in our common stock. You should read this entire prospectus supplement carefully, including the &ldquo;Risk Factors&rdquo; section
contained in this prospectus supplement, the accompanying prospectuses and in the documents we incorporate by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Our Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage
biopharmaceutical company focused on translating today&rsquo;s medical breakthroughs in cell and gene therapies into potential
cures for hematologic cancers, solid tumors and rare genetic diseases. We aim to acquire rights to these technologies by licensing
or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either
out-licensing or bringing the technologies to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our pipeline is currently
focused in three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (&ldquo;CAR&rdquo;) engineered
T cell (&ldquo;CAR T&rdquo;) therapies for hematologic malignancies and CAR T therapies for solid tumors. For each therapy we have
partnered with world class research institutions. For our gene therapy program, we have partnered with St. Jude Children&rsquo;s
Research Hospital (&ldquo;St. Jude&rdquo;) in the development of a first-in-class ex vivo lentiviral treatment of X-linked severe
combined immunodeficiency (&ldquo;XSCID&rdquo;) and for our CAR T therapies we have partnered with the City of Hope National Medical
Center (&ldquo;COH&rdquo;), Fred Hutchinson Cancer Research Center (&ldquo;Fred Hutch&rdquo;) and Nationwide Children&rsquo;s Hospital
(&ldquo;Nationwide&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>Gene Therapy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In partnership with
St. Jude, our gene therapy program is being conducted under an exclusive license to develop a potentially curative treatment for
XSCID, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. This first-in-class
ex vivo lentiviral gene therapy is currently in two Phase 1/2 clinical trials: a multicenter trial in newly diagnosed infants sponsored
by St. Jude and a single-center trial in previously transplanted patients sponsored by the National Institutes of Health (&ldquo;NIH&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2020, Mustang
submitted an IND application with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) to initiate a multicenter Phase 2 clinical
trial of MB-107 in newly diagnosed infants with XSCID who are under the age of two. The trial is expected to enroll 10 patients
who, together with 15 patients enrolled in the current multicenter trial led by St. Jude Children&rsquo;s Research Hospital, will
be compared with 25 matched historical control patients who have undergone hematopoietic stem cell transplant (&ldquo;HSCT&rdquo;).
The primary efficacy endpoint will be event-free survival. The initiation of this trial is currently on hold pending CMC clearance
by the FDA. Mustang is targeting topline data from the trial in the second half of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mustang further expects
to file an IND in the third quarter of 2020 for a registrational multi-center Phase 2 clinical trial of its lentiviral gene therapy
in previously transplanted XSCID patients. This product will be designated MB-207. Mustang anticipates enrolling 20 patients and
comparing them to matched historical control patients who have undergone a second HSCT. Mustang is targeting topline data for this
trial in the second half of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>CAR T Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our pipeline of CAR
T therapies is being developed under exclusive licenses from several world class research institutions. Our strategy is to license
these technologies, support preclinical and clinical research activities by our partners and transfer the underlying technology
to our cell processing facility located in Worcester, Massachusetts, to conduct our own clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing
CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred
Hutch targeting CD20 (MB-106). Phase 1 clinical trials sponsored by COH for MB-102 and MB-104 and by Fred Hutch for MB-106
are underway. In the third quarter of 2019 the FDA approved our IND application to initiate a multicenter Phase 1/2 clinical
trial of MB-102, and our clinical trial is expected to begin enrollment in the second quarter of 2020 for the treatment of
patients with acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and high-risk myelodysplastic syndrome.
We expect to file an IND for MB-104 in the first half of 2021 and to initiate our own Phase 1 clinical trial shortly
thereafter for the treatment of patients with multiple myeloma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also plan to file
an IND and initiate our own clinical trial for MB-106 for the treatment of patients with non-Hodgkin lymphoma and chronic lymphocytic
leukemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also developing
CAR T therapies for solid tumors in partnership with COH targeting IL13R&alpha;2 (MB-101), HER2 (MB-103) and PSCA (MB-105). In addition,
we have partnered with Nationwide for the C134 oncolytic virus (MB-108) in order to enhance the activity of MB-101 for the treatment
of patients with GBM. Phase 1 clinical trials sponsored by COH for MB-101, MB-103 and MB-105 are underway. A Phase 1 clinical trial
sponsored by the University of Alabama at Birmingham (&ldquo;UAB&rdquo;) for MB-108 began during the third quarter of 2019 and,
in the first half of 2021, we plan to file an IND for the combination of MB-101 and MB-108 for the treatment of patients with GBM.
We also plan to file INDs and initiate our own clinical trials for MB-103 for the treatment of patients with metastatic breast
cancer to brain and for MB-105 for the treatment of patients with prostate and pancreatic cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231F20"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a majority-controlled
subsidiary of Fortress Biotech, Inc. (&ldquo;Fortress&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at 377 Plantation Street, Worcester, Massachusetts 01605, and our telephone number is 781-652-4500. We maintain
a website on the Internet at www.mustangbio.com and our e-mail address is info@mustangbio.com. Our Internet website, and the information
contained on it, are not to be considered part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_004"></A>THE OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Mustang Bio, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Common stock offered by us pursuant to this prospectus supplement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10,769,231 shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Common stock to be outstanding after the offering </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">52,846,071 shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Option to Purchase Additional Shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted the underwriters an option for a period of up
    to 30 days from the date of this prospectus supplement to purchase up to an aggregate of 1,615,384 additional shares of our
    common stock at the price set forth on the cover page of this prospectus supplement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds of this offering to continue preclinical developments and clinical trials of our product candidates and for general corporate purposes. See the section titled &ldquo;Use of Proceeds&rdquo; on page S-8 of this prospectus supplement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Global Market Symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">MBIO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
of common stock to be outstanding after the offering assumes no exercise of the underwriters&rsquo; option to purchase additional
shares of common stock and is based on 42,076,840 shares of common stock outstanding as of March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
of our common stock to be outstanding immediately after this offering is based on 42,076,840 shares of our common stock outstanding
as of March 31, 2020. The number of shares outstanding as of March 31, 2020 excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">1,787,164 shares of common stock shares of common stock reserved for future issuance under our incentive
plan and employee stock purchase plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">980,667 shares of common stock issuable upon the vesting of restricted stock units;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">1,241,675 shares issuable upon exercise of outstanding options with a weighted average exercise price
of $5.73 per share; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">5,402,670 shares issuable upon exercise of outstanding warrants with a weighted average exercise price
of $8.21 per share.</TD></TR>                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_005"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investment in our common stock involves
risks. Before deciding whether to invest in our common stock, you should consider carefully the risk factors discussed below and
those contained in the section entitled &ldquo;Risk Factors&rdquo; contained in our <A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000110465920034130/tm205359d1_10k.htm" STYLE="-sec-extract: exhibit">Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 16, 2020,</A> which is incorporated herein by reference in its entirety, together
with other information in the accompanying prospectuses, the information and documents incorporated by reference herein and therein,
and in any free writing prospectus that we have authorized for use in connection with this offering. If any of the risks or uncertainties
described in our SEC filings actually occurs, our business, financial condition, results of operations or cash flow could be materially
and adversely affected. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of
your investment. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also affect our business operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Risks Associated with this Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have broad discretion in the use of the net proceeds
of this offering and may not use them effectively.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the
net proceeds from this offering for general corporate purposes and to continue preclinical development and clinical trials of our
product candidates. However, our management will have broad discretion in the application of the net proceeds from this offering
and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The
failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect
on our business, cause the price of our common stock to decline and delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">You will experience immediate and substantial dilution.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the offering
price per share in this offering exceeds the net tangible book value per share of our common stock, you will suffer substantial
dilution in the net tangible book value of the common stock you purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Founders
Agreement with Fortress, you will also experience immediate dilution by virtue of the shares issuable to Fortress in connection
with this offering; specifically, we will immediately issue to Fortress a number of shares of our common stock equal to 2.5% of
the gross amount of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may experience future dilution as a result of future
equity offerings.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities
in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors
purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at
which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions
may be higher or lower than the price per share paid by investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fortress will continue to control a voting majority of
our common stock following the offering.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of the Class A Preferred Stock held by Fortress, Fortress is entitled to cast, for each share of Class A Preferred Stock held by
Fortress, the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of the
shares of outstanding common stock and the denominator of which is the number of shares of outstanding Class A Preferred Stock.
Accordingly, as long as Fortress owns any shares of Class A Preferred Stock, it will be able to control or significantly influence
all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business
combination transactions. The consummation of this offering will not impact Fortress&rsquo;s holdings of Class A Preferred Stock,
so Fortress will continue to be able to exercise such control and influence over the Company. The interests of Fortress may not
always coincide with the interests of other stockholders, and Fortress may take actions that advance its own interests and are
contrary to the desires of our other stockholders. Moreover, this concentration of voting power may delay, prevent or deter a change
in control of us even when such a change may be in the best interests of all stockholders, could deprive our stockholders of an
opportunity to receive a premium for their common stock as part of a sale of Mustang or our assets, and might affect the prevailing
market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our stock price can be volatile, which increases the
risk of litigation, and may result in a significant decline in the value of your investment.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of
our common stock has been and is likely to continue to be highly volatile and subject to wide fluctuations in price in response
to various factors, many of which are beyond our control. These factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements relating to the clinical development of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements concerning the progress of our efforts to obtain regulatory approval for and commercialize
our product candidates or any future product candidate, including any requests we receive from the FDA, or comparable regulatory
authorities outside the United States, for additional studies or data that result in delays in obtaining regulatory approval or
launching these product candidates, if approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the depth and liquidity of the market for our common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">investor perceptions about us and our business;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology sectors or the economy as a whole;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">price and volume fluctuations in the overall stock market;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the failure of one or more of our product candidates or any future product candidate, if approved,
to achieve commercial success;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments concerning product development results or intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">litigation or public concern about the safety of our potential products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements of the introduction of new products by us or our competitors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual fluctuations in our quarterly operating results, and concerns by investors that such fluctuations
may occur in the future;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">deviations in our operating results from the estimates of securities analysts or other analyst
comments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments concerning current or future strategic collaborations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">discussion of us or our stock price by the financial and scientific press and in online investor
communities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">health care reform legislation, including measures directed at controlling the pricing of pharmaceutical
products, and third-party coverage and reimbursement policies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">additions or departures of key personnel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, equity
markets in general, and the market for biotechnology and life sciences companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies traded in
those markets. These broad market and industry factors may materially affect the market price of our common stock, regardless of
our development and operating performance. In the past, following periods of volatility in the market price of a company&rsquo;s
securities, securities class-action litigation has often been instituted against that company. Such litigation, if instituted against
us, could cause us to incur substantial costs to defend such claims and divert management&rsquo;s attention and resources, which
could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_006"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds to
us from the sale of shares of our common stock will be approximately $32.9 million or approximately $37.8 million, if the option to purchase
additional shares is exercised in full by the underwriters, in each case, after deducting underwriting discounts but excluding
offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the
net proceeds of this offering for the continued research and development of our drug products, and for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timing and amounts
of our actual expenditures will depend on several factors, including the progress of our research and development programs, the
results of other pre-clinical and clinical studies and the timing and costs of regulatory approvals. Pending the uses described
above, we will invest the net proceeds in short-term and long-term, investment grade, interest-bearing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_007"></A>DIVIDEND
POLICY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid any cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. Any future
determination to pay dividends will be at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_008"></A>DILUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in
our common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this
offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book
value of our common stock as of March 31, 2020 was approximately $45.8 million, or approximately $1.09 per share of common
stock based upon 42,076,840 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less
our total liabilities, divided by the total number of shares outstanding as of March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect
to the sale of our common stock in this offering at an offering price of $3.25 per share, and after deducting estimated offering commissions,
our net tangible book value as of March 31, 2020 would have been approximately $1.48 per share of common stock. This represents an
immediate increase in net tangible book value of $0.39 per share to our existing stockholders and an immediate dilution in net tangible
book value of $1.77 per share to new investors in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
illustrates this calculation on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-size: 10pt">Offering price per share</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"></TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right"></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">3.25</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Net tangible book value per share as of March 31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.09</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Increase in net tangible book value per share attributable to the offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.39</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">As-adjusted net tangible book value per share after giving effect to the offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.48</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Dilution in net tangible book value per share to new investors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.77</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
of our common stock to be outstanding immediately after this offering is based on 42,076,840 shares of our common stock outstanding
as of March 31, 2020. The number of shares outstanding as of March 31, 2020 excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">1,787,164 shares of common stock shares of common stock reserved for future issuance under our incentive
plan and employee stock purchase plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">980,667 shares of common stock issuable upon the vesting of restricted stock units;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">1,241,675 shares issuable upon exercise of outstanding options with a weighted average exercise price
of $5.73 per share; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">5,402,670 shares issuable upon exercise of outstanding warrants with a weighted average exercise price
of $8.21 per share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters
exercise in full their option to purchase additional shares of our common stock, the as adjusted net tangible book value after
this offering would be $1.53 per share, representing an increase
in the net tangible book value of $0.04 per share to existing stockholders
and immediate dilution in net tangible book value of $0.04 per share
to purchasers in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
any options or warrants are exercised, new options are issued under our equity incentive plan or we otherwise issue additional
shares of common stock in the future at a price less than the public offering price, there will be further dilution to new investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_009"></A>UNDERWRITING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms
and conditions set forth in the underwriting agreement, dated June , 2020, between us and Cantor Fitzgerald &amp; Co., 499 Park
Avenue, New York, New York 10022, as representative of the underwriters named below (the &ldquo;Representative&rdquo;) and the
lead book-running manager of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the shares of common stock shown opposite its name below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 82%"><B>Underwriter</B> &nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><B>Number of Shares</B> &nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Cantor Fitzgerald &amp; Co.</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">9,431,434</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Oppenheimer &amp; Co. Inc.</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,337,797</TD>
<TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; padding-left: 17.1pt">Total</TD>
<TD STYLE="font-size: 1pt">&nbsp;</TD>
<TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,769,231</TD>
<TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriting agreement
provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the
underwriters of officers&rsquo; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting
agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. We have
agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities
under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters are
offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale.
The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option to Purchase Additional Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted
to the underwriters an option, exercisable 30 days from the date of this prospectus supplement, to purchase, from time to
time, in whole or in part, up to an aggregate of 1,615,384 shares from us at the public offering price set forth on the
cover page of this prospectus supplement, less underwriting discounts and commissions. If the underwriters exercise this
option, each underwriter will be obligated, subject to certain conditions, to purchase a number of additional shares
approximately proportionate to that underwriter&rsquo;s initial purchase commitment as indicated in the table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commission and Expenses</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters have
advised us that they propose to offer the shares of common stock to the public at the public offering price set forth on the cover
page of this prospectus supplement and to certain dealers, which may include the underwriters, at that price less a concession
not in excess of $0.117 per share of common stock. After the initial offering, the Representative may change the offering price and
other selling terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds,
before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of
the underwriters&rsquo; option to purchase additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Without <BR> Option to<BR> Purchase<BR> Additional<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">With <BR> Option to<BR> Purchase<BR> Additional<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Without<BR> Option to<BR> Purchase<BR> Additional<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">With <BR> Option to<BR> Purchase<BR> Additional<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left">Public offering price</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.25</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.25</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">35,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">40,250,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Underwriting discounts and commissions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.195</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.195</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,415,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds to us, before expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.055</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.055</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">32,900,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">37,835,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate expenses
payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be
approximately $250,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Listing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
listed on the NASDAQ Global Market under the trading symbol &ldquo;MBIO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">No Sales of Similar Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, our officers, our
directors and Fortress have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90
days after the date of the underwriting agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer,
establish an open &ldquo;put equivalent position&rdquo; within the meaning of Rule 16a-l(h) under the Securities Exchange Act of
1934, as amended, or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record
or beneficially,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part,
the economic consequence of ownership of common stock, or securities exchangeable or exercisable for or convertible into shares
of common stock, or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">publicly announce an intention to do any of the foregoing for a period of 90 days after the date
of this prospectus supplement without the prior written consent of the Representative.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we and
each such person agrees that, without the prior written consent of the Representative, we or such other person will not, during
the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock
or any security convertible into or exercisable or exchangeable for common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Representative
may, in its sole discretion and at any time or from time to time before the termination of the 90-day period release all or any
portion of the securities subject to lock-up agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Market Making, Stabilization and Other Transactions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters may
make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated
to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion.
Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to
sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters have
advised us that they, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, and certain persons participating
in the offering, may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition
of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market
price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions
may involve either &ldquo;covered&rdquo; short sales or &ldquo;naked&rdquo; short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Covered&rdquo;
short sales are sales made in an amount not greater than the underwriters&rsquo; option to purchase additional shares of our common
stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase
additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of
shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available
for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Naked&rdquo;
short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out
any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters
are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing
that could adversely affect investors who purchase in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A stabilizing bid is
a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price
of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the
underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase
transactions, the underwriters&rsquo; purchases to cover the syndicate short sales may have the effect of raising or maintaining
the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result,
the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement
permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering
if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have
not been effectively placed by such syndicate member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we, nor any
of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and,
if commenced, may end any of these activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Passive Market Making</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters may
also engage in passive market making transactions in our common stock on the NASDAQ in accordance with Rule 103 of Regulation M
during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through
the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent
bid of that security. However, if all independent bids are lowered below the passive market maker&rsquo;s bid, that bid must then
be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher
than the price that otherwise would exist in the open market in the absence of those transactions. The underwriters are not required
to engage in passive market making and, if commenced, may end passive market making activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Electronic Distribution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A prospectus in electronic
format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters,
selling group members (if any) or their affiliates. The underwriters may agree with us to allocate a specific number of shares
of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&rsquo;
web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus
supplement, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Activities and Relationships</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters and
certain of their respective affiliates are full service financial institutions engaged in a wide range of activities for their
own accounts and the accounts of customers, which may include, among other things, corporate finance, mergers and acquisitions,
merchant banking, equity and fixed income sales, trading and research, derivatives, foreign exchange, futures, asset management,
custody, clearance and securities lending. The underwriters and certain of their affiliates have, from time to time, performed,
and may in the future perform, various investment banking and financial advisory services for us and our affiliates, for which
they received or will receive customary fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in the
ordinary course of its business, the underwriters and their respective affiliates may, directly or indirectly, hold long or short
positions, trade and otherwise conduct such activities in or with respect to debt or equity securities and/or bank debt of, and/or
derivative products. Such investment and securities activities may involve our securities and instruments. The underwriters and
their respective affiliates may also make investment recommendations or publish or express independent research views in respect
of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions
in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cantor Fitzgerald &amp;
Co. and Oppenheimer &amp; Co. Inc. are parties to the At Market Issuance Sales Agreement among the Company and Cantor Fitzgerald &amp; Co., B. Riley FBR, Inc.,
National Securities Corporation and Oppenheimer &amp; Co. Inc., dated July 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stamp Taxes</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you purchase shares
of common stock offered in this prospectus supplement, you may be required to pay stamp taxes and other charges under the laws
and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE TO INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
constitutes an &ldquo;exempt offering document&rdquo; as defined in and for the purposes of applicable Canadian securities laws.
No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer
and sale of the common stock. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed
upon this prospectus supplement or on the merits of the common stock and any representation to the contrary is an offence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Canadian investors
are advised that this prospectus supplement has been prepared in reliance on section 3A.3 of National Instrument 33-105 <I>Underwriting
Conflicts</I> (&ldquo;NI 33-105&rdquo;). Pursuant to section 3A.3 of NI 33-105, this prospectus supplement is exempt from the requirement
that the Company and the underwriter(s) provide investors with certain conflicts of interest disclosure pertaining to &ldquo;connected
issuer&rdquo; and/or &ldquo;related issuer&rdquo; relationships that may exist between the Company and the underwriter(s) as would
otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Resale Restrictions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offer and sale
of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement that the Company
prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired by a Canadian
investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the
relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to
a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under
a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority.
These resale restrictions may under certain circumstances apply to resales of the common stock outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Representations of Purchasers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Canadian investor
who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that the investor (i) is
purchasing the common stock as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities
laws, for investment only and not with a view to resale or redistribution; (ii) is an &ldquo;accredited investor&rdquo; as such
term is defined in section 1.1 of National Instrument 45-106 <I>Prospectus Exemptions</I> (&ldquo;NI 45-106&rdquo;) or, in Ontario,
as such term is defined in section 73.3(1) of the <I>Securities Act</I> (Ontario); and (iii) is a &ldquo;permitted client&rdquo;
as such term is defined in section 1.1 of National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Taxation and Eligibility for Investment</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any discussion of taxation
and related matters contained in this prospectus supplement does not purport to be a comprehensive description of all of the tax
considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in particular, does
not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident,
or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common stock for investment
by such investor under relevant Canadian federal and provincial legislation and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Rights of Action for Damages or Rescission</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities legislation
in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum (such as
this prospectus supplement), including where the distribution involves an &ldquo;eligible foreign security&rdquo; as such term
is defined in Ontario Securities Commission Rule 45-501 <I>Ontario Prospectus and Registration Exemptions</I> and in Multilateral
Instrument 45-107 <I>Listing Representation and Statutory Rights of Action Disclosure Exemptions</I>, as applicable, with a remedy
for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other
offering document that constitutes an offering memorandum, and any amendment thereto, contains a &ldquo;misrepresentation&rdquo;
as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised
or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and
defences under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation
from any other right or remedy available at law to the investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Language of Documents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of this
document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any
way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be
drawn up in the English language only. <I>Par la r&eacute;ception de ce document, chaque investisseur Canadien confirme par les
pr&eacute;sentes qu&rsquo;il a express&eacute;ment exig&eacute; que tous les documents faisant foi ou se rapportant de quelque
mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res d&eacute;crites aux pr&eacute;sentes (incluant, pour
plus de certitude, toute confirmation d&rsquo;achat ou tout avis) soient r&eacute;dig&eacute;s en anglais seulement</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Australia</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
is not a disclosure document for the purposes of Australia&rsquo;s Corporations Act 2001 (Cth) of Australia, or Corporations Act,
has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt
persons set out below. Accordingly, if you receive this prospectus supplement in Australia:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You confirm and warrant
that you are either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;sophisticated investor&rdquo; under section 708(8)(a) or (b) of the Corporations Act;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;sophisticated investor&rdquo; under section 708(8)(c) or (d) of the Corporations Act and
that you have provided an accountant&rsquo;s certificate to the company which complies with the requirements of section 708(8)(c)(i)
or (ii) of the Corporations Act and related regulations before the offer has been made; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;professional investor&rdquo; within the meaning of section 708(11)(a) or (b) of the Corporations
Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under the Corporations
Act any offer made to you under this prospectus supplement is void and incapable of acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You warrant and agree
that you will not offer any of the shares issued to you pursuant to this prospectus supplement for resale in Australia within 12
months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document
under section 708 of the Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">European Economic Area</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In relation to each
Member State of the European Economic Area, no offer of any securities which are the subject of the offering contemplated by this
prospectus supplement has been or will be made to the public in that Member State other than any offer where a prospectus supplement
has been or will be published in relation to such securities that has been approved by the competent authority in that Member State
or, where appropriate, approved in another Member State and notified to the relevant competent authority in that Member State in
accordance with the Prospectus Directive, except that an offer of such securities may be made to the public in that Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to any legal entity which is a &ldquo;qualified investor&rdquo; as defined in the Prospectus Directive;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to fewer than 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters
for any such offer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in any other circumstances falling within Article 3(2) of the Prospectus Directive,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no such offer of securities
shall require the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive
or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purposes of
this provision, the expression an &ldquo;offer to the public&rdquo; in relation to any securities in any Member State means the
communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered
so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Member State by
any measure implementing the Prospectus Directive in that Member State and the expression &ldquo;Prospectus Directive&rdquo; means
Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive), and includes any relevant implementing
measure in the Member State and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hong Kong</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No securities have
been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose
ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &ldquo;professional investors&rdquo;
as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a &ldquo;prospectus&rdquo; as defined in the Companies Ordinance (Cap.
32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32) of Hong
Kong. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession
of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents
of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong)
other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to
 &ldquo;professional investors&rdquo; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made
under that Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus supplement may not be issued,
circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong
Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that
he is aware of the restriction on offers of the securities described in this prospectus supplement and the relevant offering documents
and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Japan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offering has not
been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended),
or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including
any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly,
in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance
with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Singapore</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus supplement
and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the
securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an
invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore
other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the
SFA, (ii) to a relevant person as defined under Section 275(2), or any person pursuant to Section 275(1A) of the SFA, and in accordance
with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions
of any other applicable provision of the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Where the securities
are subscribed or purchased under Section 275 of the SFA by a relevant person which is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the
sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of
whom is an accredited investor; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary is an accredited investor,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">shares, debentures and units of shares
and debentures of that corporation or the beneficiaries&rsquo; rights and interest in that trust shall not be transferable for
six months after that corporation or that trust has acquired the Offer Shares under Section 275 of the SFA except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section
275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares
and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000
(or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of
securities or other assets, and further for corporations, in accordance with the conditions, specified in Section 275 of the SFA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">where no consideration is given for the transfer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">where the transfer is by operation of law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Switzerland</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities may
not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This prospectus supplement has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this prospectus supplement nor any other offering or marketing material relating to the securities or the
offering may be publicly distributed or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither this prospectus
supplement nor any other offering or marketing material relating to the offering, the Company or the securities have been or will
be filed with or approved by any Swiss regulatory authority. In particular, this prospectus supplement will not be filed with,
and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the
offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA.
The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers
of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israel</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This document does
not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or
approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed
only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli
Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio
managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity
in excess of NIS 50 million and &ldquo;qualified individuals&rdquo;, each as defined in the Addendum (as it may be amended from
time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted
under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required
to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">United Kingdom</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors (as defined in
the Prospectus Directive) that are also (i) investment professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the &ldquo;Order&rdquo;, and/or (ii) high
net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated
or caused to be communicated. Each such person is referred to herein as a &ldquo;Relevant Person&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by
recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not
act or rely on this document or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any invitation or inducement
to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the &ldquo;FSMA&rdquo;)
may only be communicated or caused to be communicated in connection with the issue or sale of the securities in circumstances in
which Section 21(1) of the FSMA does not apply. All applicable provisions of the FSMA must be complied with in respect of anything
done by any person in relation to the securities in, from or otherwise involving the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_010"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the
common stock offered hereby will be passed upon by Alston &amp; Bird LLP, New York, New York. Duane Morris LLP, New York, New York,
is counsel to the underwriters in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_011"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial
statements as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019 incorporated
by reference in this prospectus supplement have been so incorporated in reliance on the report of BDO USA, LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as
experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_012"></A>WHERE YOU
CAN FIND ADDITIONAL INFORMATION ABOUT US</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file reports with
the SEC on an annual basis using Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. You may read and copy
any such reports and amendments thereto at the SECs Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 on official
business days during the hours of 10:00 a.m. to 3:00 p.m. Please call the SEC at 1-800-SEC-0330 for information on the Public Reference
Room. Additionally, the SEC maintains a website that contains annual, quarterly, and current reports, proxy statements, and other
information that issuers (including us) file electronically with the SEC. The SECs website address is http://www.sec.gov. You can
also obtain copies of materials we file with the SEC from our Internet website found at www.mustangbio.com. Our stock is quoted
on the Nasdaq Global Market under the symbol &ldquo;MBIO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
is only part of the registration statements on Form S-3 that we have filed with the SEC under the Securities Act and therefore
omits certain information contained in the registration statements. We have also filed exhibits and schedules with the registration statements that are excluded from this prospectus supplement, and you should refer to the applicable exhibit or schedule for a
complete description of any statement referring to any contract or other document. You may inspect copies of the registration statements,
including the exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of
the fees prescribed by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><A NAME="s_013"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to
 &ldquo;incorporate by reference&rdquo; the information we file with them which means that we can disclose important information
to you by referring you to those documents instead of having to repeat the information in this prospectus supplement and accompanying
prospectuses. The information incorporated by reference is considered to be part of this prospectus supplement and accompanying
prospectuses, and later information that we file with the SEC will automatically update and supersede this information. This prospectus
supplement incorporates by reference the documents listed below (other than, unless otherwise specifically indicated, current reports
furnished under Item 2.02, Item 7.01 or Item 9.01 of Form 8-K and exhibits filed on such form that are related to such items):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000110465920034130/tm205359d1_10k.htm" STYLE="-sec-extract: exhibit">Our Annual Report on Form10-K for the fiscal year ended December 31, 2019;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000110465920059648/tm2014597d1_10q.htm" STYLE="-sec-extract: exhibit">Our Quarterly Report on Form 10-Q for the three months ended March 31, 2020;</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000110465920053522/tm2017975-1_def14a.htm" STYLE="-sec-extract: exhibit">Our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 29, 2020 (other than the portions thereof that are furnished and not filed); and</A></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The description of the Common Stock as included under the caption &ldquo;Description of Registrant&rsquo;s
Securities to be Registered&rdquo; in our <A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_10-12g.htm" STYLE="-sec-extract: exhibit">Registration Statement on Form 10-12G, as amended, originally filed with the Commission on July 28, 2016,</A> and our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1680048/000114420417044272/v473684_8a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A12B filed with the Commission on August 21, 2017</A>, and any amendment
or report filed for the purpose of further updating such description.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All reports and other
documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC,
will also be incorporated by reference into this prospectus supplement and deemed to be part of this prospectus supplement from
the date of the filing of such reports and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tm2022421d1_42b5img003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> Preferred
Stock&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may offer and sell an
indeterminate number of shares of our common stock, preferred stock, warrants to purchase our common stock, preferred stock,
debt securities, or units comprised of two or more such securities (the &ldquo;Securities&rdquo;) from time to time under this
prospectus. You should read this prospectus and any prospectus supplement carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may offer the Securities in one or more
offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell the Securities through agents
we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe
their compensation in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus provides a general description
of the Securities we may offer. Each time we sell Securities, we will provide specific terms of the Securities offered in a supplement
to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should
read this prospectus and the applicable prospectus supplement carefully before you invest in any Securities. This prospectus may
not be used to consummate a sale of Securities unless accompanied by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock are listed for trading on
the Nasdaq Capital Market under the symbol &ldquo;MBIO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act and will therefore be subject to reduced reporting requirements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investing in our Securities involves risks.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this Prospectus is July 27,
2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0.5in"><B>TABLE
OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 95%"><A HREF="#pro_01"><FONT STYLE="text-transform: uppercase">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: right"><A HREF="#pro_01"><FONT STYLE="text-transform: uppercase">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_03"><FONT STYLE="text-transform: uppercase">Important information About This Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_03"><FONT STYLE="text-transform: uppercase">2</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_04"><FONT STYLE="text-transform: uppercase">Description Of Capital Stock</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_04"><FONT STYLE="text-transform: uppercase">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_05"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_05"><FONT STYLE="text-transform: uppercase">5</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_06"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_06"><FONT STYLE="text-transform: uppercase">6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_07"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_07"><FONT STYLE="text-transform: uppercase">9</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_08"><FONT STYLE="text-transform: uppercase">Plan Of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_08"><FONT STYLE="text-transform: uppercase">10</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_09"><FONT STYLE="text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_09"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_10"><FONT STYLE="text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_10"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_11"><FONT STYLE="text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_11"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#pro_12"><FONT STYLE="text-transform: uppercase">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#pro_12"><FONT STYLE="text-transform: uppercase">11</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="pro_01"></A>SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">We are a clinical-stage biopharmaceutical
company focused on the acquisition, development and commercialization of novel cancer immunotherapy products designed to utilize
the power of the patient&rsquo;s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by
licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually
either out-licensing or bringing the technologies to market. We have partnered with the City of Hope National Medical Center (&ldquo;COH&rdquo;)
and Fred Hutchinson Cancer Research Center (&ldquo;Fred Hutch&rdquo;) in the development of proprietary chimeric antigen receptor
(&ldquo;CAR&rdquo;) engineered T cell (&ldquo;CAR T&rdquo;) therapies and related technologies across many cancers. We believe
that harnessing the body&rsquo;s own immune system to treat cancer is the next generation of cancer care that may prove curative
across tumor types that have proved resistant to standard pharmacological and biological treatments. CAR T uses the patient&rsquo;s
own T-cells to engage and destroy specific tumors. The process involves selecting specific T-cell subtypes, genetically engineering
them to express chimeric antigen T-cell receptors and placing them back in the patient where they recognize and destroy cancer
cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">In addition, we sponsor COH research for the
development of other CAR T cell constructions targeting a number of tumor-associated antigens specific for a variety of solid and
hematological malignancies. The effectiveness of certain of these additional CAR T cell constructs has already been demonstrated
in preclinical studies with mouse xenograft models of specific human tumors. Under the sponsored research arrangement, we have
the option to license newly developed CAR T constructs. We intend to further pursue preclinical development to validate and seek
to establish the proprietary nature of the most promising CAR T approaches coming out of the sponsored research program and, if
successful, license and take them forward into clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">We also hold complementary patent licenses
relating to the use, delivery and possible enhancement of our proprietary CAR technologies. In particular, we licensed intellectual
property from Harvard University pertaining to CRISPR/Cas9-enhanced CAR T therapies and hope to use technologies related to off-the-shelf
(allogeneic) CAR T development, as well as CRISPR/Cas9 gene editing platforms, in conjunction with our CAR T cell therapies to
develop treatments for hematologic malignancies and solid tumors. We have partnered with Beth Israel Deaconess Medical Center to
perform preclinical Cas9 gene editing research under a sponsored research arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">In January 2018, we entered into a non-exclusive
license agreement with COH to acquire patent and licensed know-how rights related to developing, manufacturing, and commercializing
licensed products. We are required to pay $75,000 in consideration for the licenses to the patent rights and the licensed know-how,
which we paid in March of 2018, in addition to an annual maintenance fee. Royalty payments in the low-single digits are due on
net sales of licensed products. Simultaneous with the execution of this agreement, the Company entered into a sponsored research
agreement with COH to optimize and develop CAR T cell processing procedures. Pursuant to the sponsored research agreement, we will
fund continued research in the amount of $0.9 million which we paid in March of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">In March 2018, we entered into a sponsored
research agreement with Fred Hutch related to developing and optimizing processes and systems associated with CD20 cell processing.
Pursuant to this sponsored research agreement, we will fund continued research in the amount of $0.6 million for one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">To date, we have not received approval for
the sale of our product candidates in any market and, therefore, have not generated any product sales from our product candidates.
In addition, we have incurred substantial operating losses since our inception, and expect to continue to incur significant operating
losses for the foreseeable future and may never become profitable. As of March 31, 2018, we have an accumulated deficit of $54.7
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">We are a majority controlled subsidiary of
Fortress Biotech, Inc. (&ldquo;Fortress&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.35pt; text-align: justify">Our principal executive offices are located at 2 Gansevoort Street,
9th Floor, New York, New York 10014, and our telephone number is 781-652-4500. We maintain a website on the Internet at www.mustangbio.com
and our e-mail address is info@mustangbio.com. Our Internet website, and the information contained on it, are not to be considered
part of this prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_03"></A>Important information
About This Prospectus</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In this prospectus, unless
the context suggests otherwise, references to &ldquo;Mustang Bio,&rdquo; &ldquo;Mustang,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
 &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Mustang Bio, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">This prospectus is part
of a &ldquo;shelf&rdquo; registration statement that we filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;).
By using a shelf registration statement, we may sell our securities, as described in this prospectus, from time to time in one
or more offerings. Each time we sell Securities, we will provide a prospectus supplement to this prospectus that contains specific
information about the terms of such offering. The prospectus supplement may also add, update or change information contained in
this prospectus. Before purchasing any securities, you should carefully read both this prospectus and any prospectus supplement,
together with the additional information incorporated into this prospectus or described under the heading &ldquo;<I>Where You Can
Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">You should rely only on
the information contained or incorporated by reference in this prospectus and any prospectus supplement. We have not authorized
any other person to provide you with different information. If anyone provides you with different or inconsistent information,
you should not rely on it. We will not make an offer to sell Securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus, as well as information we previously filed with the SEC and
have incorporated by reference, is accurate as of the date on the front cover of this prospectus only, or when such document was
filed with the SEC. Our business, financial condition, results of operations and prospects may have changed since the relevant
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Neither we, nor any of
our officers, directors, agents or representatives or underwriters, make any representation to you about the legality of an investment.
You should not interpret the contents of this prospectus, any prospectus supplement, or any free writing prospectus to be legal,
business, investment or tax advice. You should consult with your own advisors for that type of advice and consult with them about
the legal, tax, business, financial and other issues that you should consider before investing in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We will not use this prospectus
to offer and sell Securities unless it is accompanied by a prospectus supplement that more fully describes the terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_04"></A>Description
Of Capital Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following description
summarizes the material terms of Mustang capital stock as of the date of this registration statement. Because it is only a summary,
it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
refer to our certificate of incorporation, our bylaws and to the provisions of applicable Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our common stock is traded
on The Nasdaq Capital Market under the symbol &ldquo;MBIO.&rdquo; The closing sale price of our common stock on July 12,
2018 was $7.44 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Capital Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Company
is authorized to issue 50,000,000 shares of common stock with a par value of $0.0001 per share, of which 1,000,000 shares
are designated as Class A common stock and 2,000,000 of preferred stock at $0.0001 par value of which 250,000 are
designated as Class A preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of common
stock are entitled to one vote per share of common stock held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;The undesignated
preferred stock may be issued from time to time in one or more series. The Board of Directors is authorized to determine or alter
the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions,
if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences and relative,
participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted to or imposed
upon any wholly unissued series of preferred stock, and to fix the number of shares of any series of preferred stock (but not below
the number of shares of any such series then outstanding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Class A Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of Class A
common stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class
A common shares held by such holder are convertible. For a period of ten years from issuance, the holders of the Class A common
stock have the right to appoint one member of the board of directors of Mustang. To date, the holders of Class A common stock have
not yet appointed such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Class A Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Class A Preferred
Stock is identical to undesignated common stock other than as to voting rights, conversion rights, and the PIK dividend right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of the outstanding
shares of Class A Preferred Stock receive on each March 13 (each a &ldquo;PIK Dividend Payment Date&rdquo;) after the original
issuance date of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock
or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable
shares of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK dividend is equal to
2.5% of the Corporation&rsquo;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK
Dividend Payment Date (&ldquo;PIK Record Date&rdquo;). In the event the Class A Preferred Stock converts into common stock, the
holders shall receive all PIK dividends accrued through the date of such conversion. No dividend or other distribution shall be
paid, or declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock) on the
shares of common stock until all PIK dividends on the Class A Preferred Stock shall have been paid or declared and set apart for
payment. All dividends are non-cumulative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On any matter presented
to the stockholders for their action or consideration at any meeting of stockholders (or by written consent of stockholders in
lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class
A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number
of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the number of shares
of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A Common Stock
and the Class A Preferred Stock are convertible, and the denominator of which is number of shares of outstanding Class A Preferred
Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each share of Class A
Preferred Stock is convertible, at the option of the holder, into one fully paid and nonassessable share of common stock, subject
to certain adjustments. If the Company, at any time effects a subdivision or combination of the outstanding common stock (by any
stock split, stock dividend, recapitalization, reverse stock split or otherwise), the applicable conversion ratio in effect immediately
before that subdivision is proportionately decreased or increased, as applicable, so that the number of shares of common stock
issuable on conversion of each share of Class A Preferred Stock shall be increased or decreased, as applicable, in proportion to
such increase or decrease in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization, recapitalization,
reclassification, consolidation or merger involving the Company occurs in which the common stock (but not the Class A Preferred
Stock) is converted into or exchanged for securities, cash or other property, then each share of Class A Preferred Stock becomes
convertible into the kind and amount of securities, cash or other property which a holder of the number of shares of common stock
of the Company issuable upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization, recapitalization,
reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B><I>Additional Features</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Other features of our
capital stock include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Dividend Rights.</I> The holders of outstanding shares of our common stock, including Class A common stock, are entitled
to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine.
All dividends are non-cumulative.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Voting Rights.</I> The holders of our common stock are entitled to one vote for each share of common stock held on all matters
submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not
provide for cumulative voting rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>No Preemptive or Similar Rights</I>. The holders of our common stock have no preemptive, conversion, or subscription rights,
and there are no redemption or sinking fund provisions applicable to our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Right to Receive Liquidation Distributions</I>. Upon our liquidation, dissolution, or winding-up, the assets legally available
for distribution to our stockholders would be distributable ratably among the holders of our common stock, including Class A common
stock, outstanding at that time after payment of other claims of creditors, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Fully Paid and Non-Assessable.</I> All of the outstanding shares of our common stock, including Class A common stock, and
the Class A Preferred Stock are duly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_05"></A>DESCRIPTION
OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">We may issue
warrants to purchase shares of our common stock or preferred stock in one or more series together with other securities
or separately, as described in each applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">The prospectus supplement relating to any warrants
we offer will include specific terms relating to the offering. These terms will include some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the aggregate number of warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation, number and terms of the shares of common stock purchasable upon exercise of the warrants and procedures by
which those numbers may be adjusted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the exercise price of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the dates or periods during which the warrants are exercisable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and terms of any securities with which the warrants are issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if the warrants are issued as a unit with another security, the date on and after which the warrants and the other security
will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the
exercise price is denominated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any minimum or maximum amount of warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any terms relating to the modification of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any terms, procedures and limitations relating to the transferability, exchange or exercise of the warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other specific terms of the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_06"></A>DESCRIPTION
OF DEBT SECURITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We may offer debt securities
which may be senior, subordinated or junior subordinated and may be convertible. Unless otherwise specified in the applicable prospectus
supplement, our debt securities will be issued in one or more series under an indenture to be entered into between us and a trustee.
We will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be
entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will
include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement
in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The following description
briefly sets forth certain general terms and provisions of the debt securities that we may offer. The particular terms of the debt
securities offered by any prospectus supplement and the extent, if any, to which these general provisions may apply to the debt
securities, will be described in the related prospectus supplement. Accordingly, for a description of the terms of a particular
issue of debt securities, reference must be made to both the related prospectus supplement and to the following description.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The aggregate principal
amount of debt securities that may be issued under the indenture is unlimited. The debt securities may be issued in one or more
series as may be authorized from time to time pursuant to a supplemental indenture entered into between us and the trustee or an
order delivered by us to the trustee. For each series of debt securities we offer, a prospectus supplement accompanying this prospectus
will describe the following terms and conditions of the series of debt securities that we are offering, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>title and aggregate principal amount;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the debt securities will be senior, subordinated or junior subordinated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>applicable subordination provisions, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provisions regarding whether the debt securities will be convertible or exchangeable into other securities or property of the
Company or any other person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">percentage or percentages of principal amount at which the debt securities will be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maturity date(s);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interest rate(s) or the method for determining the interest rate(s);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether interest on the debt securities will be payable in cash or additional debt securities of the same series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">dates on which interest will accrue or the method for determining dates on which interest will accrue and dates on which interest
will be payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the amount of payment of principal of, premium, if any, or interest on the debt securities may be determined with reference
to an index, formula or other method;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">redemption, repurchase or early repayment provisions, including our obligation or right to redeem, purchase or repay debt securities
under a sinking fund, amortization or analogous provision;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than the debt securities&rsquo; principal amount, the portion of the principal amount of the debt securities that
will be payable upon declaration of acceleration of the maturity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorized denominations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>form;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">amount of discount or premium, if any, with which the debt securities will be issued, including whether the debt securities
will be issued as &ldquo;original issue discount&rdquo; securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the place or places where the principal of, premium, if any, and interest on the debt securities will be payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">where the debt securities may be presented for registration of transfer, exchange or conversion;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the place or places where notices and demands to or upon the Company in respect of the debt securities may be made;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the debt securities will be issued in whole or in part in the form of one or more global securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if the debt securities will be issued in whole or in part in the form of a book-entry security, the depository or its nominee
with respect to the debt securities and the circumstances under which the book-entry security may be registered for transfer or
exchange or authenticated and delivered in the name of a person other than the depository or its nominee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether a temporary security is to be issued with respect to such series and whether any interest payable prior to the issuance
of definitive securities of the series will be credited to the account of the persons entitled thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms upon which beneficial interests in a temporary global security may be exchanged in whole or in part for beneficial
interests in a definitive global security or for individual definitive securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the guarantors, if any, of the debt securities, and the extent of the guarantees and any additions or changes to permit or
facilitate guarantees of such debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any covenants applicable to the particular debt securities being issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any defaults and events of default applicable to the debt securities, including the remedies available in connection therewith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">currency, currencies or currency units in which the purchase price for, the principal of and any premium and any interest on,
such debt securities will be payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">time period within which, the manner in which and the terms and conditions upon which the Company or the purchaser of the debt
securities can select the payment currency;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">securities exchange(s) on which the debt securities will be listed, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether any underwriter(s) will act as market maker(s) for the debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">extent to which a secondary market for the debt securities is expected to develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provisions relating to defeasance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provisions relating to satisfaction and discharge of the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any restrictions or conditions on the transferability of the debt securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued
under the indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any addition or change in the provisions related to compensation and reimbursement of the trustee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">provisions, if any, granting special rights to holders upon the occurrence of specified events;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the debt securities will be secured or unsecured, and, if secured, the terms upon which the debt securities will be
secured and any other additions or changes relating to such security; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other terms of the debt securities that are not inconsistent with the provisions of the Trust Indenture Act (but may modify,
amend, supplement or delete any of the terms of the indenture with respect to such series of debt securities).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">One or more series of debt
securities may be sold as &ldquo;original issue discount&rdquo; securities. These debt securities would be sold at a substantial
discount below their stated principal amount, bearing no interest or interest at a rate which at the time of issuance is below
market rates. One or more series of debt securities may be variable rate debt securities that may be exchanged for fixed rate debt
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">United States federal income
tax consequences and special considerations, if any, applicable to any such series will be described in the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Debt securities may be issued
where the amount of principal and/or interest payable is determined by reference to one or more currency exchange rates, commodity
prices, equity indices or other factors. Holders of such debt securities may receive a principal amount or a payment of interest
that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending upon the value
of the applicable currencies, commodities, equity indices or other factors. Information as to the methods for determining the amount
of principal or interest, if any, payable on any date, the currencies, commodities, equity indices or other factors to which the
amount payable on such date is linked and certain additional United States federal income tax considerations will be set forth
in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The term &ldquo;debt securities&rdquo;
includes debt securities denominated in U.S. dollars or, if specified in the applicable prospectus supplement, in any other freely
transferable currency or units based on or relating to foreign currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We expect most debt securities
to be issued in fully registered form without coupons and in denominations of $1,000 and any integral multiples thereof. Subject
to the limitations provided in the indenture and in the prospectus supplement, debt securities that are issued in registered form
may be transferred or exchanged at the principal corporate trust office of the trustee, without the payment of any service charge,
other than any tax or other governmental charge payable in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">The debt securities of
a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf
of, a depositary identified in the prospectus supplement. Global securities will be issued in registered form and in either temporary
or definitive form. Unless and until it is exchanged in whole or in part for the individual debt securities, a global security
may not be transferred except as a whole by the depositary for such global security to a nominee of such depositary or by a nominee
of such depositary to such depositary or another nominee of such depositary or by such depositary or any such nominee to a successor
of such depositary or a nominee of such successor. The specific terms of the depositary arrangement with respect to any debt securities
of a series and the rights of and limitations upon owners of beneficial interests in a global security will be described in the
applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">The indenture and the debt
securities shall be construed in accordance with and governed by the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_07"></A>DESCRIPTION
OF UNITS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We may issue, in one
more series, units comprised of shares of our common stock,  preferred stock, warrants to purchase common stock or
preferred stock, debt securities or any combination of those securities. Each unit will be issued so that the holder of the unit
is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of
a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included
in the unit may not be held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We may evidence units by
unit certificates that we issue under a separate agreement. We may issue the units under a unit agreement between us and one or
more unit agents. If we elect to enter into a unit agreement with a unit agent, the unit agent will act solely as our agent in
connection with the units and will not assume any obligation or relationship of agency or trust for or with any registered holders
of units or beneficial owners of units. We will indicate the name and address and other information regarding the unit agent in
the applicable prospectus supplement relating to a particular series of units if we elect to use a unit agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We will describe in the
applicable prospectus supplement the terms of the series of units being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any provisions of the governing unit agreement that differ from those described herein; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the
units.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The other provisions
regarding our common stock,  preferred stock, warrants and debt securities as described in this section will apply to each
unit to the extent such unit consists of shares of our common stock, warrants and/or debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_08"></A>Plan Of Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">We may sell the securities covered in this
prospectus in any of three ways (or in any combination):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through underwriters or dealers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>directly to a limited number of purchasers or to a single purchaser; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through agents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Each time that we use
this prospectus to sell securities, we will also provide a prospectus supplement that contains the specific terms of the offering.
The prospectus supplement will set forth the terms of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the name or names of any underwriters, dealers or agents and the amounts of any securities underwritten or purchased by each
of them; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the public offering price of the common stock and the proceeds to us and any discounts, commissions or concessions allowed
or reallowed or paid to dealers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Any public offering price
and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">If underwriters are used
in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be resold from
time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices
determined at the time of sale. The securities may be either offered to the public through underwriting syndicates represented
by managing underwriters, or directly by underwriters. Generally, the underwriters&rsquo; obligations to purchase the securities
will be subject to certain conditions precedent. The underwriters will be obligated to purchase all of the securities if they purchase
any of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We may sell the securities
through agents from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities
and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We may authorize underwriters,
dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement
will set forth any commissions we pay for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Agents and underwriters
may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933,
as amended, or to contribution with respect to payments which the agents or underwriters may be required to make in respect thereof.
Agents and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We may enter into derivative
transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities
covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party
may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings
of securities, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of securities. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus
supplement (or a post-effective amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_09"></A>Legal Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Certain legal matters
will be passed upon for us by Alston &amp; Bird LLP, New York, New York. Additional&nbsp;legal matters may be passed upon for us
or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_10"></A>Experts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The financial statements as of December 31, 2017 and 2016 and for each of the two years in the period
ended December 31, 2017 incorporated by reference in this Prospectus have been so incorporated in reliance on the report of BDO
USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The balance sheet of Mustang
Bio, Inc. as of December 31, 2015 and the related statements of operations, stockholders&rsquo; equity and cash flows for the period
from March 13, 2015 (inception) to December 31, 2015 have been audited by Mayer Hoffman McCann P.C., independent registered public
accounting firm, as stated in their report which is incorporated herein. Such financial statements have been incorporated herein
in reliance on the report of such firm given upon their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_11"></A>Where You Can
Find More Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have filed with the
SEC, Washington, D.C. 20549, a registration statement on Form S-3 under the Securities Act with respect to the common stock offered
hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules
thereto. For further information with respect to the Company and its common stock, reference is made to the registration statement
and the exhibits and any schedules filed therewith. Statements contained in this prospectus as to the contents of any contract
or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit,
reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement
being qualified in all respects by such reference. A copy of the registration statement, including the exhibits and schedules thereto,
may be read and copied at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the
operation of the Public Reference Room may be obtained by calling the Securities and Exchange Commission (the &ldquo;SEC&rdquo;
or &ldquo;Commission&rdquo;) at 1-800-SEC-0330. In addition, the SEC maintains an Internet site at www.sec.gov, from which interested
persons can electronically access the registration statement, including the exhibits and any schedules thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are subject to the
information reporting requirements of the Exchange Act, and we file periodic reports and other information with the SEC. All documents
filed with the SEC are available for inspection and copying at the addresses set forth above. We also maintain an Internet site
at <U>www.mustangbio.com</U>. Our website and the information contained therein or connected thereto shall not be deemed to be
incorporated into this prospectus or the registration statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><A NAME="pro_12"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with them which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus and accompanying prospectus. The information
incorporated by reference is considered to be part of this prospectus and accompanying prospectus, and later information that we
file with the SEC will automatically update and supersede this information. This prospectus incorporates by reference the documents
listed below (other than, unless otherwise specifically indicated, current reports furnished under Item 2.02 or Item 7.01 of Form
8-K and exhibits filed on such form that are related to such items):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2017;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">Our Current Reports on Form 8-K filed with the SEC on March 29, 2018, May 15, 2018
                                                                and                                                                 June 15, 2018 (excluding
                                                                any                                                                                                     information furnished
                                                                pursuant to Item 2.02 or Item                                                                 9.01);
                                                                and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">The description of the Common Stock as included under the caption &ldquo;Description of Registrant&rsquo;s
Securities to be Registered&rdquo; in our Registration Statement on Form 10-12G, as amended, originally filed with the Commission
on July 28, 2016, and our Registration Statement on Form 8-A12B filed with the Commission on August 21, 2017, and any amendment
or report filed for the purpose of further updating such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">All reports and other
documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC,
will also be incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tm2022421d1_42b5img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may offer and sell an indeterminate number
of shares of our common stock, preferred stock, warrants to purchase our common stock, preferred stock, debt securities, or units
comprised of two or more such securities (the &ldquo;Securities&rdquo;) from time to time under this prospectus. You should read
this prospectus and any prospectus supplement carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may offer the Securities in one or more
offerings in amounts, at prices, and on terms determined at the time of the offering. We may sell the Securities through agents
we select or through underwriters and dealers we select. If we use agents, underwriters or dealers, we will name them and describe
their compensation in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus provides a general description
of the Securities we may offer. Each time we sell Securities, we will provide specific terms of the Securities offered in a supplement
to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should
read this prospectus and the applicable prospectus supplement carefully before you invest in any Securities. This prospectus may
not be used to consummate a sale of Securities unless accompanied by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock are listed for trading on
the Nasdaq Global Market under the symbol &ldquo;MBIO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth
company&rdquo; as defined in the Jumpstart Our Business Startups Act and a &ldquo;smaller reporting company&rdquo; as defined in
the Exchange Act, and will therefore be subject to reduced reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Investing in our Securities involves risks.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of
this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The date of this
Prospectus is September 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; text-transform: uppercase">SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><A HREF="#a_001"><FONT STYLE="font-size: 10pt; text-transform: uppercase">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Important information About This Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt; text-transform: uppercase">2</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Description Of Capital Stock</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt; text-transform: uppercase">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt; text-transform: uppercase">6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt; text-transform: uppercase">9</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Plan Of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt; text-transform: uppercase">10</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt; text-transform: uppercase">11</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<DIV STYLE="border: Black 1pt solid; padding: 3pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage
biopharmaceutical company focused on translating today&rsquo;s medical breakthroughs in cell and gene therapies into potential
cures for hematologic cancers, solid tumors and rare genetic diseases. We aim to acquire rights to these technologies by licensing
or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either
out-licensing or bringing the technologies to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our pipeline is currently
focused in three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (&ldquo;CAR&rdquo;) engineered
T cell (&ldquo;CAR T&rdquo;) therapies for hematologic malignancies and CAR T therapies for solid tumors. For each therapy we have
partnered with world class research institutions. For our gene therapy programs, we have partnered with St. Jude Children&rsquo;s
Research Hospital (&ldquo;St. Jude&rdquo;) in the development of a first-in-class ex vivo lentiviral treatment of X-linked severe
combined immunodeficiency (&ldquo;XSCID&rdquo;) and for our CAR T therapies we have partnered with the City of Hope National Medical
Center (&ldquo;COH&rdquo;), Fred Hutchinson Cancer Research Center (&ldquo;Fred Hutch&rdquo;) and Nationwide Children&rsquo;s Hospital
(&ldquo;Nationwide&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><I>Gene Therapy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In partnership with St.
Jude, our gene therapy program (MB-107) is being conducted under an exclusive license to develop a potentially curative treatment
for XSCID, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. This
first-in-class ex vivo lentiviral gene therapy is currently in two Phase&nbsp;1/2 clinical trials sponsored by St. Jude and the
National Institutes of Health (&ldquo;NIH&rdquo;). Results in these two trials have been promising and we plan to transfer St.
Jude&rsquo;s Investigational New Drug Application (&ldquo;IND&rdquo;) to Mustang in the second half of 2019 following completion
of the technology transfer process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><I>CAR T Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Mustang&rsquo;s pipeline
of CAR T therapies is being developed under exclusive licenses from several world class research institutions. Our strategy is
to license these technologies, support preclinical and clinical research activities by our partners and transfer the underlying
technology to our cell processing facility located in Worcester, Massachusetts to conduct Mustang sponsored clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are developing CAR T therapies for hematologic malignancies
in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Phase 1 clinical
trials sponsored by COH for MB-102 and by Fred Hutch for MB-106 are underway, and a COH sponsored Phase 1 clinical trial for MB-104
opened in April 2019. The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) recently approved our IND application to initiate
a multi-center Phase 1/2 clinical trial of MB-102, and our clinical trial will begin later in 2019. We expect to file an IND for
MB-104 in the second half of 2019 and to initiate our own Phase 1 clinical trial shortly thereafter for the treatment of patients
with multiple myeloma. We also plan to file an IND and initiate our own clinical trial for MB-106 for the treatment of patients
with non-Hodgkin lymphoma and chronic lymphocytic leukemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are also developing CAR T therapies for solid tumors in partnership
with COH targeting IL13R&alpha;2 (MB-101), HER2 (MB-103) and PSCA (MB-105). In addition, we have partnered with Nationwide for the C134
oncolytic virus (MB-108) in order to enhance the activity of MB-101 for the treatment of patients with glioblastoma multiforme
(&ldquo;GBM&rdquo;). Phase 1 clinical trials sponsored by COH for MB-101 and MB-103 are underway, and a COH sponsored Phase 1 clinical
trial for MB-105 opened for accrual of patients with prostate cancer in the second quarter of 2019. A Phase 1 clinical trial sponsored
by the University of Alabama at Birmingham for MB-108 is scheduled to commence in the second half of 2019. We also plan to file
INDs and initiate our own clinical trials for MB-103 for the treatment of patients with metastatic breast cancer to brain, for
MB-105 for the treatment of patients with prostate and pancreatic cancer and for the combination of MB-101 and MB-108 for the treatment
of patients with GBM.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Additionally, we hold
complementary patent licenses relating to the use, delivery and possible enhancement of our proprietary CAR technologies. In particular,
we licensed intellectual property from Harvard University pertaining to CRISPR/Cas9 gene editing of CAR T cells, and we hope to
use this technology to enhance the activity of our CAR T cell therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">To date, we have not
received approval for the sale of our product candidates in any market and, therefore, have not generated any product sales from
our product candidates. In addition, we have incurred substantial operating losses since our inception, and expect to continue
to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2019, we have
an accumulated deficit of $99.1&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We are a majority-controlled subsidiary of
Fortress Biotech, Inc. (&ldquo;Fortress&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Our principal executive offices are located at 2 Gansevoort Street,
9th&nbsp;Floor, New York, New York 10014, and our telephone number is 781-652-4500. We maintain a website on the Internet at www.mustangbio.com
and our e-mail address is info@mustangbio.com. Our Internet website, and the information contained on it, are not to be considered
part of this prospectus.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</DIV>




<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>Important
information About This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In this prospectus, unless
the context suggests otherwise, references to &ldquo;Mustang Bio,&rdquo; &ldquo;Mustang,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
 &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Mustang Bio, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">This prospectus is part
of a &ldquo;shelf&rdquo; registration statement that we filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;).
By using a shelf registration statement, we may sell our securities, as described in this prospectus, from time to time in one
or more offerings. Each time we sell Securities, we will provide a prospectus supplement to this prospectus that contains specific
information about the terms of such offering. The prospectus supplement may also add, update or change information contained in
this prospectus. Before purchasing any securities, you should carefully read both this prospectus and any prospectus supplement,
together with the additional information incorporated into this prospectus or described under the heading &ldquo;<I>Where You Can
Find More Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">You should rely only on
the information contained or incorporated by reference in this prospectus and any prospectus supplement. We have not authorized
any other person to provide you with different information. If anyone provides you with different or inconsistent information,
you should not rely on it. We will not make an offer to sell Securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus, as well as information we previously filed with the SEC and
have incorporated by reference, is accurate as of the date on the front cover of this prospectus only, or when such document was
filed with the SEC. Our business, financial condition, results of operations and prospects may have changed since the relevant
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Neither we, nor any of
our officers, directors, agents or representatives or underwriters, make any representation to you about the legality of an investment.
You should not interpret the contents of this prospectus, any prospectus supplement, or any free writing prospectus to be legal,
business, investment or tax advice. You should consult with your own advisors for that type of advice and consult with them about
the legal, tax, business, financial and other issues that you should consider before investing in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We will not use this prospectus
to offer and sell Securities unless it is accompanied by a prospectus supplement that more fully describes the terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>Description
Of Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following description
summarizes the material terms of Mustang capital stock as of the date of this registration statement. Because it is only a summary,
it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
refer to our certificate of incorporation, our bylaws and to the provisions of applicable Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our common stock is
traded on The Nasdaq Capital Market under the symbol &ldquo;MBIO.&rdquo; The closing sale price of our common stock on August
14, 2019 was $3.73 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Capital Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Company is authorized
to issue 85,000,000 shares of common stock with a par value of $0.0001 per share, of which 1,000,000 shares are designated as Class
A common stock and 2,000,000 of preferred stock at $0.0001 par value of which 250,000 are designated as Class A preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of common
stock are entitled to one vote per share of common stock held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The undesignated
preferred stock may be issued from time to time in one or more series. The Board of Directors is authorized to determine or alter
the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions,
if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences and relative,
participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted to or imposed
upon any wholly unissued series of preferred stock, and to fix the number of shares of any series of preferred stock (but not below
the number of shares of any such series then outstanding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Class A Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of Class A
common stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class
A common shares held by such holder are convertible. For a period of ten years from issuance, the holders of the Class A common
stock have the right to appoint one member of the board of directors of Mustang. To date, the holders of Class A common stock have
not yet appointed such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Class A Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Class A Preferred
Stock is identical to undesignated common stock other than as to voting rights, conversion rights, and the PIK dividend right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The holders of the outstanding
shares of Class A Preferred Stock receive on each March 13 (each a &ldquo;PIK Dividend Payment Date&rdquo;) after the original
issuance date of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock
or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable
shares of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK dividend is equal to
2.5% of the Corporation&rsquo;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK
Dividend Payment Date (&ldquo;PIK Record Date&rdquo;). In the event the Class A Preferred Stock converts into common stock, the
holders shall receive all PIK dividends accrued through the date of such conversion. No dividend or other distribution shall be
paid, or declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock) on the
shares of common stock until all PIK dividends on the Class A Preferred Stock shall have been paid or declared and set apart for
payment. All dividends are non-cumulative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On any matter presented
to the stockholders for their action or consideration at any meeting of stockholders (or by written consent of stockholders in
lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class
A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number
of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the number of shares
of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A Common Stock
and the Class A Preferred Stock are convertible, and the denominator of which is number of shares of outstanding Class A Preferred
Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each share of Class A Preferred Stock
is convertible, at the option of the holder, into one fully paid and nonassessable share of common stock, subject to certain adjustments.
If the Company, at any time effects a subdivision or combination of the outstanding common stock (by any stock split, stock dividend,
recapitalization, reverse stock split or otherwise), the applicable conversion ratio in effect immediately before that subdivision
is proportionately decreased or increased, as applicable, so that the number of shares of common stock issuable on conversion of
each share of Class A Preferred Stock shall be increased or decreased, as applicable, in proportion to such increase or decrease
in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization, recapitalization, reclassification,
consolidation or merger involving the Company occurs in which the common stock (but not the Class A Preferred Stock) is converted
into or exchanged for securities, cash or other property, then each share of Class A Preferred Stock becomes convertible into the
kind and amount of securities, cash or other property which a holder of the number of shares of common stock of the Company issuable
upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization, recapitalization, reclassification,
consolidation or merger would have been entitled to receive pursuant to such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Additional Features</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Other features of our
capital stock include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Dividend Rights.</I> The holders of outstanding shares of our common stock, including Class A common stock, are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine. All dividends are non-cumulative.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Voting Rights.</I> The holders of our common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>No Preemptive or Similar Rights</I>. The holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Right to Receive Liquidation Distributions</I>. Upon our liquidation, dissolution, or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock, including Class A common stock, outstanding at that time after payment of other claims of creditors, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Fully Paid and Non-Assessable.</I> All of the outstanding shares of our common stock, including Class A common stock, and the Class A Preferred Stock are duly issued, fully paid and non-assessable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may issue warrants
to purchase shares of our common stock or preferred stock in one or more series together with other securities or separately, as
described in each applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The prospectus supplement
relating to any warrants we offer will include specific terms relating to the offering. These terms will include some or all of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the title of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the aggregate number of warrants offered;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the designation, number and terms of the shares of common stock purchasable upon exercise of the warrants and procedures by which those numbers may be adjusted;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the exercise price of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the dates or periods during which the warrants are exercisable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the designation and terms of any securities with which the warrants are issued;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if the warrants are issued as a unit with another security, the date on and after which the warrants and the other security will be separately transferable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the exercise price is denominated;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any minimum or maximum amount of warrants that may be exercised at any one time;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any terms relating to the modification of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any terms, procedures and limitations relating to the transferability, exchange or exercise of the warrants; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any other specific terms of the warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may offer debt securities
which may be senior, subordinated or junior subordinated and may be convertible. Unless otherwise specified in the applicable prospectus
supplement, our debt securities will be issued in one or more series under an indenture to be entered into between us and a trustee.
We will issue the debt securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be
entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will
include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as
in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement
in which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following description
briefly sets forth certain general terms and provisions of the debt securities that we may offer. The particular terms of the debt
securities offered by any prospectus supplement and the extent, if any, to which these general provisions may apply to the debt
securities, will be described in the related prospectus supplement. Accordingly, for a description of the terms of a particular
issue of debt securities, reference must be made to both the related prospectus supplement and to the following description.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The aggregate principal
amount of debt securities that may be issued under the indenture is unlimited. The debt securities may be issued in one or more
series as may be authorized from time to time pursuant to a supplemental indenture entered into between us and the trustee or an
order delivered by us to the trustee. For each series of debt securities we offer, a prospectus supplement accompanying this prospectus
will describe the following terms and conditions of the series of debt securities that we are offering, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">title and aggregate principal amount;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether the debt securities will be senior, subordinated or junior subordinated;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">applicable subordination provisions, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provisions regarding whether the debt securities will be convertible or exchangeable into other securities or property of the Company or any other person;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">percentage or percentages of principal amount at which the debt securities will be issued;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">maturity date(s);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">interest rate(s) or the method for determining the interest rate(s);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether interest on the debt securities will be payable in cash or additional debt securities of the same series;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">dates on which interest will accrue or the method for determining dates on which interest will accrue and dates on which interest will be payable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether the amount of payment of principal of, premium, if any, or interest on the debt securities may be determined with reference to an index, formula or other method;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">redemption, repurchase or early repayment provisions, including our obligation or right to redeem, purchase or repay debt securities under a sinking fund, amortization or analogous provision;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if other than the debt securities&rsquo; principal amount, the portion of the principal amount of the debt securities that will be payable upon declaration of acceleration of the maturity;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">authorized denominations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">form;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">amount of discount or premium, if any, with which the debt securities will be issued, including whether the debt securities will be issued as &ldquo;original issue discount&rdquo; securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the place or places where the principal of, premium, if any, and interest on the debt securities will be payable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">where the debt securities may be presented for registration of transfer, exchange or conversion;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the place or places where notices and demands to or upon the Company in respect of the debt securities may be made;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether the debt securities will be issued in whole or in part in the form of one or more global securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if the debt securities will be issued in whole or in part in the form of a book-entry security, the depository or its nominee with respect to the debt securities and the circumstances under which the book-entry security may be registered for transfer or exchange or authenticated and delivered in the name of a person other than the depository or its nominee;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether a temporary security is to be issued with respect to such series and whether any interest payable prior to the issuance of definitive securities of the series will be credited to the account of the persons entitled thereto;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the terms upon which beneficial interests in a temporary global security may be exchanged in whole or in part for beneficial interests in a definitive global security or for individual definitive securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the guarantors, if any, of the debt securities, and the extent of the guarantees and any additions or changes to permit or facilitate guarantees of such debt securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any covenants applicable to the particular debt securities being issued;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any defaults and events of default applicable to the debt securities, including the remedies available in connection therewith;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">currency, currencies or currency units in which the purchase price for, the principal of and any premium and any interest on, such debt securities will be payable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">time period within which, the manner in which and the terms and conditions upon which the Company or the purchaser of the debt securities can select the payment currency;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">securities exchange(s) on which the debt securities will be listed, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether any underwriter(s) will act as market maker(s) for the debt securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">extent to which a secondary market for the debt securities is expected to develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provisions relating to defeasance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">provisions relating to satisfaction and discharge of the indenture;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any restrictions or conditions on the transferability of the debt securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any addition or change in the provisions related to compensation and reimbursement of the trustee;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provisions, if any, granting special rights to holders upon the occurrence of specified events;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether the debt securities will be secured or unsecured, and, if secured, the terms upon which the debt securities will be secured and any other additions or changes relating to such security; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other terms of the debt securities that are not inconsistent with the provisions of the Trust Indenture Act (but may modify, amend, supplement or delete any of the terms of the indenture with respect to such series of debt securities).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">One or more series of debt
securities may be sold as &ldquo;original issue discount&rdquo; securities. These debt securities would be sold at a substantial
discount below their stated principal amount, bearing no interest or interest at a rate which at the time of issuance is below
market rates. One or more series of debt securities may be variable rate debt securities that may be exchanged for fixed rate debt
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">United States federal income
tax consequences and special considerations, if any, applicable to any such series will be described in the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Debt securities may be issued
where the amount of principal and/or interest payable is determined by reference to one or more currency exchange rates, commodity
prices, equity indices or other factors. Holders of such debt securities may receive a principal amount or a payment of interest
that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending upon the value
of the applicable currencies, commodities, equity indices or other factors. Information as to the methods for determining the amount
of principal or interest, if any, payable on any date, the currencies, commodities, equity indices or other factors to which the
amount payable on such date is linked and certain additional United States federal income tax considerations will be set forth
in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The term &ldquo;debt securities&rdquo;
includes debt securities denominated in U.S. dollars or, if specified in the applicable prospectus supplement, in any other freely
transferable currency or units based on or relating to foreign currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We expect most debt securities
to be issued in fully registered form without coupons and in denominations of $1,000 and any integral multiples thereof. Subject
to the limitations provided in the indenture and in the prospectus supplement, debt securities that are issued in registered form
may be transferred or exchanged at the principal corporate trust office of the trustee, without the payment of any service charge,
other than any tax or other governmental charge payable in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">The debt securities of
a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf
of, a depositary identified in the prospectus supplement. Global securities will be issued in registered form and in either temporary
or definitive form. Unless and until it is exchanged in whole or in part for the individual debt securities, a global security
may not be transferred except as a whole by the depositary for such global security to a nominee of such depositary or by a nominee
of such depositary to such depositary or another nominee of such depositary or by such depositary or any such nominee to a successor
of such depositary or a nominee of such successor. The specific terms of the depositary arrangement with respect to any debt securities
of a series and the rights of and limitations upon owners of beneficial interests in a global security will be described in the
applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">The indenture and the debt
securities shall be construed in accordance with and governed by the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may issue, in one more
series, units comprised of shares of our common stock, preferred stock, warrants to purchase common stock or preferred stock, debt
securities or any combination of those securities. Each unit will be issued so that the holder of the unit is also the holder of
each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may evidence units by
unit certificates that we issue under a separate agreement. We may issue the units under a unit agreement between us and one or
more unit agents. If we elect to enter into a unit agreement with a unit agent, the unit agent will act solely as our agent in
connection with the units and will not assume any obligation or relationship of agency or trust for or with any registered holders
of units or beneficial owners of units. We will indicate the name and address and other information regarding the unit agent in
the applicable prospectus supplement relating to a particular series of units if we elect to use a unit agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We will describe in the
applicable prospectus supplement the terms of the series of units being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any provisions of the governing unit agreement that differ from those described herein; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The other provisions regarding
our common stock, preferred stock, warrants and debt securities as described in this section will apply to each unit to the extent
such unit consists of shares of our common stock, warrants and/or debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>Plan
Of Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">We may sell the securities covered in this
prospectus in any of three ways (or in any combination):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">through underwriters or dealers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">directly to a limited number of purchasers or to a single purchaser; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">through agents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each time that we use
this prospectus to sell securities, we will also provide a prospectus supplement that contains the specific terms of the offering.
The prospectus supplement will set forth the terms of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the name or names of any underwriters, dealers or agents and the amounts of any securities underwritten or purchased by each of them; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the public offering price of the common stock and the proceeds to us and any discounts, commissions or concessions allowed or reallowed or paid to dealers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Any public offering price
and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If underwriters are used
in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be resold from
time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices
determined at the time of sale. The securities may be either offered to the public through underwriting syndicates represented
by managing underwriters, or directly by underwriters. Generally, the underwriters&rsquo; obligations to purchase the securities
will be subject to certain conditions precedent. The underwriters will be obligated to purchase all of the securities if they purchase
any of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may sell the securities
through agents from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities
and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may authorize underwriters,
dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement
will set forth any commissions we pay for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Agents and underwriters
may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act of 1933,
as amended, or to contribution with respect to payments which the agents or underwriters may be required to make in respect thereof.
Agents and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We may enter into derivative
transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities
covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party
may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings
of securities, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of securities. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus
supplement (or a post-effective amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Certain legal matters
will be passed upon for us by Alston &amp; Bird LLP, New York, New York. Additional&nbsp;legal matters may be passed upon for us
or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>Experts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The financial
statements as of December 31, 2018 and 2017 and for each of the two years in the period ended December 31, 2018 incorporated
by reference in this Prospectus have been so incorporated in reliance on the report of BDO USA, LLP, an independent
registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in
auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>Where
You Can Find More Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We have filed with the
SEC, Washington, D.C. 20549, a registration statement on Form S-3 under the Securities Act with respect to the common stock offered
hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules
thereto. For further information with respect to the Company and its common stock, reference is made to the registration statement
and the exhibits and any schedules filed therewith. Statements contained in this prospectus as to the contents of any contract
or other document referred to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit,
reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each statement
being qualified in all respects by such reference. A copy of the registration statement, including the exhibits and schedules thereto,
may be read and copied at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the
operation of the Public Reference Room may be obtained by calling the Securities and Exchange Commission (the &ldquo;SEC&rdquo;
or &ldquo;Commission&rdquo;) at 1-800-SEC-0330. In addition, the SEC maintains an Internet site at www.sec.gov, from which interested
persons can electronically access the registration statement, including the exhibits and any schedules thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are subject to the
information reporting requirements of the Exchange Act, and we file periodic reports and other information with the SEC. All documents
filed with the SEC are available for inspection and copying at the addresses set forth above. We also maintain an Internet site
at <U>www.mustangbio.com</U>. Our website and the information contained therein or connected thereto shall not be deemed to be
incorporated into this prospectus or the registration statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information we file with them which means that we can disclose important information to you by referring
you to those documents instead of having to repeat the information in this prospectus and accompanying prospectus. The information
incorporated by reference is considered to be part of this prospectus and accompanying prospectus, and later information that we
file with the SEC will automatically update and supersede this information. This prospectus incorporates by reference the documents
listed below (other than, unless otherwise specifically indicated, current reports furnished under Item 2.02 or Item 7.01 of Form
8-K and exhibits filed on such form that are related to such items):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419014624/tv515572_10k.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2018;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419025065/tv520179_10q.htm" STYLE="-sec-extract: exhibit">Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019;</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419038877/tv526214_10q.htm" STYLE="-sec-extract: exhibit">Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019;</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Current Reports on Form 8-K filed
with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419018182/tv518144_8k.htm" STYLE="-sec-extract: exhibit">April 4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419022388/tv520192_8k.htm" STYLE="-sec-extract: exhibit">April 30, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420419031510/tv523804_8k.htm" STYLE="-sec-extract: exhibit">June 19, 2019</A> (excluding any information furnished pursuant to Item 2.02 or
Item 9.01); and&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of the Common Stock as included under the caption &ldquo;Description of Registrant&rsquo;s Securities to be Registered&rdquo; in our Registration Statement on Form 10-12G, as amended, originally filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_10-12g.htm" STYLE="-sec-extract: exhibit">July 28, 2016</A>, and our Registration Statement on Form 8-A12B filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1680048/000114420417044272/v473684_8a12b.htm" STYLE="-sec-extract: exhibit">August 21, 2017</A>, and any amendment or report filed for the purpose of further updating such description.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">All reports and other
documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC,
will also be incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>10,769,231
shares</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2022421d1_42b5img001.jpg" ALT="" STYLE="height: 114pt; width: 173.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Mustang Bio, Inc.</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>Sole
Book-Running Manager</I></FONT><BR>
<FONT STYLE="font-size: 18pt"><B>Cantor</B></FONT><I><BR>
<BR>
Lead Manager</I><BR>
<FONT STYLE="font-size: 16pt"><B>Oppenheimer &amp; Co.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 11, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2022421d1_42b5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022421d1_42b5img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< :\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;25KMKG&(U&,^IHJ34HWM8*<'&=KW.P%% HKE.L**** "BBB@ HHHH ****
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M3%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)!XF\*VUX[ W*C9,/]H5U5<C5G9G<FFKH****0PHHHH **** "BBB@ HHHH
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2022421d1_42b5img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022421d1_42b5img002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ E #7 P$1  (1 0,1 ?_$ +@  0 " @(# 0$
M       ("0<*!08" P0!"P$!  (" P$!              8'! 4" P@!"1
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M2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA'4[W"]#6U(AC[T/W6*?\
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M0B***9U5553%(FDDF43J**',(%(0A0$1$1H !KZ 29#;'PD)$S@!&NU\D?\
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M/LGN,HN.OC+.$,$60]M\;MLBSRQ%NOV%MVNA*1Z#@KLD<LA'( S*OYG>9R)
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MI7UQBOT5%4C+4,M+3TI2?HB,F3^)G$5:#E+FONP[9M:)CT%'$A/)2+^%0:D
M!&H"611;"J8?Z2;:F'H :E5IUCK--0BEMU0\\^HR2C*%D_TDQ%[MH_1SM.NH
MN5,RTPD3*IE 'L($04X?73QB#D?>C3$<1/.+-LAFG%1UT7*]*[;$N"4%D)',
M6T.W17;-#MW"J916[@_4!@-36^UBN^/4Z6+JIKS4I"G4MB4A*82H@D%4I$RE
MLD<8C^D&;$S4JJ+.ASRJ92TI9F"9R*D@XA,P0)[1B,(FMGO'H98Y)<;X1TD1
MW;]B(3>2IX%"E4:F(T+*MHH5M]4C)*R2"5=U0$H_MK3:>N1L^E[H^@E-34E#
M");<2DJZ?E)C>7^V>;ZEMC2P#3TV=Y<\1L4$_P!0$6'\.N!G%GE!E)AR$8HV
MT:4PQ?K%4REG+I)#(W%"*L94&,DU;+FCEXT#'(FL<$:F,!R 8#%&D0OVL]5:
M>M:[ \IWP]6R>ZYC)*IB8)[P.\8\#*)IIS1.F=0W1&H&T-<ZD?VMX36F1DH#
M C<<.(G.-DHA")D(FF4")IE*0A"A0I2$ "E*4/T H!0-4D<<3MB] )"0V1Y:
M0BL_E_\ %CQTYBS4',7D28M0R$TVD[M0M S)B2]&S9-8I64F#AJY(W$YU1$Z
MJ!4U3 (U-6@A/-)^H5[TB5+HLCB\A2@KF<A,L1(B>S89B(!JWTZL>KPE%=G;
M1G!7D(&<">!F#[1(Q,3 _'7#/&:R&N/<)6'#V);*!4!6:QA5U'$BX;H@B5Y)
MOWBSEZ^="6OU**&VU$"T#IJ.7S4%WU'6&OO+ZWZDSQ,I '<   !U")+8M.V;
M35$+?9&$,4PE,)G,D;U$DDGK,9LUIHW4-(0TA#2$-(0TA#2$0U^0?+J6#>&7
M(3(QW(-58W'TI$,UMP$.1]=1D;6:'2$1 0537F ,40Z@):AX:EV@[2;WJ^@M
MTIA3Z5'J1WS[DQ#O4"[BQZ-N%RG)2:=21UN=P>]4?RZ)6(++JK/W*JHR;HYG
M#IT8PG,Y=*B*BRR^\3&.=10PB(UK4=>_KEIRW5TRVD-.[ 4[,-DQ]4H_.>CN
M]73_ #GF).)!VS.W'ZXZ2]B'K"HJI[TOT53J8E/_ ,J?T#_A74"N-AN%NFM2
M<['WD_2-T2>DNE+5@ '*YP/T<8VMO^-K8;.W<:<WN0,FW;J),+5M^TH==XBF
MHW2=L&5U2$H7^4IDS[TI-N!@_8>NJ']37R[66^VI)Q65&724@? QZ*]&:5+-
M'=+NL R;2@3&\!9/Q$4N?)=R;OGF-E]SQTX]1TK<^,[#F5"S+J"2.M'71=)5
M**/7CMN55-.&B=H@B(B)3"J>M:!K;VBB%,WXAW^ZH8#@/KC$O-:NJ=\*Q/(D
MXGB>/5PCNW!3XZE[=NP;ER=/6PM>YF"2]JVV[8.)FW8Y^FH110986T@P5DW"
M9MHD(0Z0!M-4!_3>HOKUG:<6TE9;=&1:D$)6$';E)! G+$RC3)T\U<G$!\HY
MC9S("@5)S<5 $3EN$XLOR9Q5Y49'1.R<<J6L5"[>RC;\!:(PD6@W#H1!(J<F
M=PFF0M   4\ UV6K5VD;6H.)M!6_O6MS,HGC\LI]D?;KI35MS&3S<-,[,B&\
MJ9>TGWQ$*4^)S+#M91<<PVS++',)S*R;&2554,/6HG<S2VT1'4V9]8[.A(3X
M%U"?PJ2/@B(*]Z.7AQ96:]M:B=JDJ)]ZXZ^3XM.1,*L5U Y%M)%PD;<DJRDW
MT8<#!U P F_,7_J ZR3ZN:9J$Y:FE>*3M! 5]$8Z?2+4M.O/35C04-A&9/\
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M]7UQM],6M3CANE2)DGN3WG>?A*+.M0V)U#2$-(0TA#2$-(1XF,4A3'.8"D*
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M:5L?'[F 7A\DV%;4FZQ+=J[@BR5T69#)#(/(*5.N<JY9>$!10R2@"IW43D3
MI=E1@&NM-^%<5>J:7(6H9T\%'"8Z#\8GWIUJHUK0L59/Q#8/+5Q2,<IZ1NXC
MJC;LU6L6O#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA$!<\<'[5RSD&^+\:D8MC9(PQD/%=YQJR102DU[LLV?M=C-#
MM3,!W**,HBF;=U B(" CX:DE'J%^GMJ;<N92V^EQ!X24%$=6$^LQ&*[3C%3<
MU7%,@IQA;:QQS)4D'KQ'LC0)Y??&GSD^%J\<?<J(K(%I0R(WD[3L>[L=W+(J
M2<2^&4.NU@9>/=1T*LX9N(T6X.4TS*)'*8Q3#0*ZMJV7ZSZJ:7;U(43D[R5#
M X;0<=\Y125VTW?=&O-W1#B G/W5(49C'800-VW:(V\OA8^:JW_D?@WN)\EP
MJ%F\E;(A49*8:1^T;<OJ&23$KFX8&IB+M'395(?-M3)[$BG3,0Y]Q@)6FJM*
M+L2Q4TYST"S(3VI/ _08MC1NLVM1MFEJ$Y+DVF9&Y0^\/I&Z+_M0R)Y#2$-(
M0TA#2$-(0TA#2$-(0TA'S+.VR"B22RQ$U%Q J)##0RAA&E"!3ZA_R\-)3CY,
M;(^G2/L8@SMFJT>/>,+ERS?0NPMBU6P.I+R)"*NNT-?]E,YB H?Z>@5J/Z:V
M%KMM1=JU%!2RYZS(3V1KKM=*:ST*[A5S\.V)F49'M^>BKH@XFXH-XA(1$TP;
M24<];*%50<-72154E$U"")3!M-0:> A36&ZTMAU3+H(<22".D1FLO-OM)>:(
M4VH @C>#'3,PY8M#!V-KLRI?;WR%K6=&FDY58HD[QD@432*DW(<Q>\NH=0-I
M0ZCU_;61;Z&HN=8W0THF^XJ0C%N=QIK30N7"L.6G:3,F.?LJ\HB^K*MB_(DQ
MDH2Z[?BKDCC.C)D.2/F&2+YJ*YBG,D4X(KEK0PA7]==533N4U2NE<_N(64F7
M$&4=U+4MU=*W5M_VG$!0GP4)B.Q@]9CVZ.VP]X:(T72'NB(5 $Z'^L1 *]*Z
MZLJN!PCOS)XB/-1PW1,0BRZ*1U*]LJBI"&/3J.PIC )J!^VO@!.(!E D#:1'
MZDNBN F0626*4PD,9)0B@%,%!$HB01 #  ^'CH01M@"#LCX7,U#LW*;-W+1C
M5XJ "DU<OVJ#E0!&@"F@JJ54X"/[!KD&W%)S)22GC(RCBIUI*LJE)"N!(G'V
M'<MDS$(HX03,J F3*=5,IE"EI42 8P"< J%::XR)V QR*DC:1'[YAOX]]'_^
M4G_[:2/"&8<1'Z1=!0PD362.<"[A(10AC 6H!N$I1$=M1\=)$;83!V0%= %@
M;BLD#@R8JE0%0G>%(#;15!*N\4P-TW4I721E/=#,)Y9C-'MU\C[$..7W!3C%
MSUM6V+0Y)6:YON LR4D):WD(^Z)VWQCY.1;MVKQ?O0$@S,LH9%J0**;@+MZ4
M'6TMEWN%F<4[0+R+6)' &8[1&HNUEME]:2U<4<QI!)$B1(GJ,0TXX_![P3X>
MYVM7D/@:)OFP;WMGSK1L"V2;NDXJ1CI,$BOHA^RE9Q5J[:.P1*!B'(8!H'36
MUK=67FZ4:J&L*7&E?@$Q+>)"-/;M%6*SUJ;A0)6V\G\:B#/=B=AX1<:FN@L)
MRI+)*F3IW"IJ$.)-U=N\"B(EK3I747((VQ+@0=AC\<.6[1(Z[I=%L@F%3K.%
M2(I$#]SJ*&*0H?YCH 29 3,"I*1-1 $?$RFX:2,)(Z7C) Q:U*R?M71@IXU!
M!500IKDIMQ&*TJ Z01'%+K2S)"DD]!!C$V<\X0> K/?7]=<!<<E:<.@+J=EH
M%LU>$A6H'!,7+QNHZ1='2 3 (BD13:'4>E=<(YQ$B-^47CL\M.(R,]CLAP^+
MIJ0",:Y*>6C(.+4([[_EC$<N8XCQTW*5<!)N.D4HF 0 1'2$6"6Q=5NWI;D1
M=UK2[*<MN=8I2<1,L%BJLGS%8!%-PBJ% $O00&M!*(" T$!TA'+ ]9B4I@=M
MA*<=I# NEM.8? I1WT,(_L&D(^G2$<8M-0S=R#)>6C$'AAH5HL_:IN1']@0.
MJ541_P!-(1PMYWM 6)"K3<\\(@B "1HV*(&=2+H0_B:,T@^I5501"H_TD+4Q
MA H"(<VVU.*RIC@M:6QF5$1)3(MP74_2G:.&G;/OC$&HF$D4D0U4SF,6A!6-
M_4<YO]P1%,HF* !K,#2$@IGA\8Q2ZI:LTL!&7;6S<TG8&X(UZNA'WE#P,L]9
MD5&B$L+)@X63>-*EH8Q%$OY$Z;@_:@AKI4P4J$IY"8[$/A22#\X!B$OS)*S\
MYQ1C,3V@)#7?FC+&/,?6^@<VTKIS+SC=J= PU+M34%T0#"(@ !XZF'I]RF;Z
M:Y_^Q3L..*/#*)SB#>I1==T^FW4_^IJJAMM(XS5+Z8Q5\*7)27O?#-P\:,D*
MK-,H\=9,MO\ D)(5"2*UI.2G"-!3S ]]RZ9/6CH5AZB5-1.M $-9_J+9D4UP
M1>:0 T56G-,; K?[01+MC7^E][=JK8NQUN%=1*RR.W(=D^D$&?9&'/F[R=?.
M0[+N+CWBA0RD?BNT?OAGAXF(@DS@4%FT3:=NJJIF #+39Y5VMV35$P-*TZ:S
M_3>CIJ2I1=JW^X^YR6!Q5M4K^60$^F-;ZI5U16TR[-13+=.WSZ@[@D2"$]:I
MDRZ(LK^/"Y&F6."F!32E7:/VSM^U94J2Z[<YUH2+:1SHA7#95-PD8%$:5*<I
M@_?4/U:PJ@U-5!&!YRE#M)(B;Z-?1<=)T97BGD)2?Y0 <=L5A?'#ZM._)%S(
MM&=NR]IZT\8KWH-C6]-7I=$I$P!D,A14:W%LR>RJR"H-H]THB3N%-0IOWU-=
M7E#6D+=4--M)>?"<Z@A(*NX29D#B)Q M$\UW7%TIW77ET[!7D2I:B$_J 8 F
M6PRBQ[Y2V9VW"W,UX1DC-P=T6?;J4K;LY 3LO!2$:\)),RF437BGK,RA3IF,
M4Q3[@$!U$-$*!U'3,+2E3#BY*2I(4")'B#$VU^DITM55#:EH?;;FE25%)!F.
M!$<(TO2[,'_&DIE#':,E-7W%8*7O5N\E7<E<KU2X%+>5?*S+HTHN^<.P:+%!
M44QW$$"TVTZ:YJIZ>YZQ\'5R12*JLA  2,N:4A*75'6FKJ;7H;Q]$"NK329P
M22HYLL\QG,G'&(=\),>\8^<'&UK*3N6KZN7DG.1,BMD&66RU>T%>EJ7<Y,X4
M*ZA;587!',FD+&D,F*7EV8M3"4P"(B!@"0ZDJKUIN\%#5.TBSH4.6.4A2%(&
MY2BDDDXSF9Q&=*T=AU58PIZH=7?%I)</.6E:%G>E(4 $C"4A*+!+MX1164B8
MM)D[)F2G*.,++&VV;.SKZNFT"S,HZ,CY^<FW\%(QLC)KBFS1!(%E#@4=_0*Z
MBC&I'*+GFB99"GG,Q*T)7(#8D!0(&TSE$SJ=+-5X8%<^^0PUE 0XM$R=JE%)
M!)P$IQ3/=>*&\1\LUL<6V>1LU!AM_9-OR[VW3YBR*+E9\\C7#AT<)8;D-)D*
MJJF T!6@4Z!JPV*Y3NA'+VMFF\Q#I 5RF]@.&&67NBLJJW(9]0VK AZJ\L4R
M%%/.<G,B?S9I^^+P\*\0K8P%DV7OVSKYR-)0DU9Z]OR5L7Q?ET7FP;/0DHQ\
MA,1QKDDI$S)0B# R9Z'"H*#^E=5K<K^_=:--+4-,I<2YF"D(2@RD1(Y0)[8M
M2UZ;I[/7*JZ5U]32F\I0MQ:Q.8.89B9'"7;%-V7><63+3^16Q,U',_1XHHWO
M(\7F;P'*PP\W.I"ZC[A?"U26\N8\/>K9<WF1)T11INVZL*@TW0U&D7;:)&^\
ML5)XA/V1VH(PXF*SN.JJ^FUJU=#,:>YII09X%6(43U+!QX"-DQNNBZ00=-E2
M+MW**:[=9(P'3616(51)5,X5 Q%"& 0$/$!U3Y!29' B+O!"@%)Q21&KEA?Y
M$,J\4.367T\SLKDN+B5?.<;CM:/O%<'DP%B76U1B1= Q=B==9%@@S=(*+,1K
M4@U13 YQ$;JN.DZ&^V:G\N*$7YJE2HHP',3CM'' R/MBA;7K.OT]?*GS0.+T
MX]5J0%F:N6L!,Y''"1!(]@G&P%FHUGY<XZ7;<$#->LP,I9,E.VU<=K3SMKO$
M&1UFK^-EH1Z@IO(<E/I.-# (#U#55V_Q%ONS;;B<KJ7 %)4F>_$$$1<%T--<
M;*X\RO,TIHJ2I"B-V!!28AAP+R/#8E^.2!Y Y"F9V6.VLV0O2\9V>G):>D7Q
MVQQ31+WY5ZZ.D0RJA2%*3:4-WAJ1ZJI%UVKUVND2A(+H0A*4A($^H"(MI"N;
MMVAV[Q6*6HAHK6I2E*)EUDQA?AA;60/D@@)SE#R2O&\HW'4M=$Q"8KPG8]TR
M]DV[%0T.\5;+/K@=VJ]C)>:>G$$RIBLZ5(8HF$>M!UL=1OTFD'$V.SMMFK2A
M)=>6D+45$;$A0*4CJ C6Z88K-;,JO][==31*<*6F&U*0D)29344D*)ZR8DEF
M;XTL;3ML+N\(W7E;$N1(M5K(P,M!9=R$NQ>N&;E)<\;*Q\W<LA'K-'Z)#)&,
M) $NZM0UIK;K"L9?";BVP_1JF%!32)B8V@A(,QMC>730U"^QFM;E13UJ2"E2
M7G)&1V$*4008RAS-92D9P)RU'3:IEYJ/PH9C+KF5[YEI-K!-V\@J9?<?O&4=
M)G$3U'=6M1KJ)U"D+J%K:P;*U$=1)E[HFE,AQNG;0Z9NI0D$\2 )^^*2\-<A
M<*0/Q%'PQ=DF1U?-XM;HM&VH:0BI%&,;7/<,Q((P$DO/NVA(%@VC'CI)<ZZC
MA,J5!&H" TZ8[HO=X,XF+B+B/AO&KJYH^\AB[-13=SD-)I2<0\/(*+N5DXJ1
M9K*(K-4 7[8&3.(;RFH.D(JRXX)2+OY;<[8Y>7->;ZP;/8W/+VY:3V\[H=0<
M4]3&(\N=%BXEE$E$VPK'V$.!BAN'II")0\U.460GW(7$?![!<Y[4O/)[E%SD
M2_$46SB1L^TEVWF4"10.DW"2+R30(K_,"8J)"0*"6HU0B03[X]L"REN&B9)]
ME5[/G:@F:^5,OY()<XOME/4RJ(W,FP37%7ZQ3*B"->FVG32$5LXBS-E;B3S;
MCN%_(*XE<QXHO1TFKB2\KT1;2]P099&/$T<)I)TF#QX919P6/7[@J?RF-MH6
MFOH4I/RDB<?" =HB_1&W8%N0R:,-&))G*4AR$8MBD,0AQ4(4Q03H($.-0_;]
M-,RN)AE3P$?+[/M7ND7]NPH+)E.0BP1K0%2$5J"Q2J D!P*L4:'"OU!T'IK[
MG7Q,?,B. BLGG.X4NWEK\>^+VX J1#+4QDN50ZFJUL\L$^9*G3 ?Z4G#500,
M/AJ;::3R+#=:TX'D!L?SY@8@&K#XC45FH1C*I4Z>I&4CX17-S@:S/QO?(98?
M,ZT(IZXQ3F<'K#),1&D,FW7EC*)(W W%- IFZ*KQHLR%IN)7>"FVHUI+M-J;
MUAI1W3M0H>/IR"V3P^S[#.?9$,U2ES1.LFM34X)MU5,.I&PJ^T/81+MB9=@8
M)N+('!OE'E_)48JGEGE[;DS>\XR<D'S5OVJ!5'UFV<FFH7O-D8)!PO\ QC3J
MH%0Z:CM5<V:74M%049_P*!80"/M*V+7_ #2'LB34=I>J]*W"XUPE<+DA3B@=
MJ4;4(_EF<(]OP1WP:Z>#[&$7/N=6=?UW1QBB?<=-F\D5%X\I@K] "BD(@'Z!
MIZG4W(U*IT#NN-(/NQCYZ2U1?THEI1FIIU8["<(CC\?;A.QOEOYRV9<1BQTU
M<S*ZY>&:NA[*KYK(WM S[,6Q%-IEC+Q(]\H%J(I )O -;?58\3H.UU#/>:;*
M02-Q"%),^W"-+HTBD]1;O3O]UUP**0<)@K2H>[&+&?E>EF<9P.SJV75)YV?A
MX>VX5GO+YB3FIVXHF,C6#-*N]=PX=.BE I0$>NHEH5"EZHI5 =U"BI1X)2DD
MD]0$37U!6E&DJM)^9: E(WE2E  #B23&?,0C XZXR87@LB^4;,G=CX^L]\SD
MT"+MG,G=#!A'-H=VW5*9,X.G3T$#D. A41 0UJJ\.5=YJ7*294'7%@C@DDD@
M] $XW%MY-%8J5FLD$EIM!!&!*@!(@\2911]\AOQQ1O%MA/<U^(%\3F(YVSY)
M"Y;BLN.?F2A'"97)GRSJ%$QBF$"B4PF:.A=)*@(%(0.H#9>D=7+O:T::O[27
MVG4Y$K([W"1^L2(WF*HUGHIO3Z%ZJTVZJG>:.=2 >[MF2/J,QP$7S<8LC3V7
M>/N(<F70P",N&]+'AIR78@F=(&[YTB(+%!-01.3>)-U!_?577FD:H+K44;)F
MTVZ4@] BW;%6/7"STU;4#*\ZTE2ATF*0\@'*7Y[K, 1ZFQS:Q0_Q$89X-/\
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M<:<G,,<U,2Y5@6]PVQ(\L,CH%*H4OG(=ZI;%H)HRT0Y$#&9R3,]#D.%2B8H
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M^M?'IJ/:>\W\U:\DS>/S82V=O1QB4:F\E\F>\_R^79>]/;_+^+A''<%OM?\
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GSGNSUA?[I^\]WW3]P]X_?]Z=WZ?,=VM/+?VWAM_32$3QTA#2$?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2022421d1_42b5img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022421d1_42b5img003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ DP#. P$1  (1 0,1 ?_$ ,    $#! ,!
M       '" D! @,*! 4&"P$  00# 0$               0%!@<! @,("1
M  4# P,"! ('!04( P   0(#! 41!@< $@@A,1-!"5$B,A1A%7&!0B,S-!:1
MH5(7"K'!T6)R\.&20U-C1"4D-1@1  $"! 0"!P0&"0,#!0    $  A$#! 4A
M,1(&05%A<2(R$Q0'@9&AP?"QT4(C,^'Q4H*20R05"&)R-,*3%K)S@V0E_]H
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M,;: C\.H_&E*]OCK$<=/%'"*C3Y.^Z+@?BPZDV%[8XY-W2_C3*E7)COC[?\
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MD^UZJ3YZ]W1KJ<LU-$N+#AC#5VLQ@%YPW-ZM[GD5)HK90:3JTDO >!'",,!
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M(5Z:N&EV);9,GQJ0=L8_3!4]5;[N53.\&K/X8SQ_2N)'0EL&23681L2JV62
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M]0,I33U9-P>EU.X/J*:O=.Y^&S/_ +B:ZZR>ID]IE2*BB;)(AWWY?]M,U?\
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M-KH"R8UYK'# @ CWDCZDX?VFL\WAA;+UG9=R;<<G,N\YR1F>4)67<&.*MOW
MNFC!*HMCG(FT9VVY*@LF5,H$ JXE+42B&F?U:M5O;1^3M#0#+[1CAGB80BE_
MHS?+M+FB=<W!TE[G  8F$<(Q 6[>@?S%(JF8IT5"$.D<H[BF(8 ,4Y3!]0&*
M-0'7F6<YS6!K(>+$1Y=*]3R?%>\S7$>$1AS7+$*AUUC0#WL2E$2,E8) IT_W
M_P#?K4R6'/)9+GPPA% %$.G2GZ_^&NC6,8.P,5S_ !'=Z$%> 4#0(PQS6P
M@,E765E&A"-"$:$(T(6)00"HCUH 5#]??2>=JE1J&G(06(,F'PG9YK63_P!3
M;F(UL\8,/X;9NBD=Y6RH$Q(M2*B"J\#8,:>14 Z9*F\ R+]O\QJ$W%IJ^O\
M':W,.Y'768.ZV$3ECT] 7G'_ "+NSI=A;:F.(CB0%H_N'K-MN^[630  ,()[
MMYS%ZT /'7YA#MKV565-ML[2^7-#SGG'YKQ9)M<]Q!@<5T3FXFYR*$;M2N"@
M0P%47IL(40H:I1"O4HB%?34:G[OHZ^7.I9\L!CI3P'0AVH8?%.]/:*C6'-U
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MEW2O2$L:98'(+N-;+9&A"-"$:$(T(1H0C0A&A"-"%B,4HFZ@/4NT1ZTI6O\
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MB& -1*ZS[Q9'Z+C13W,.$07C/J:IUM:3MRX0?:VB7,,#VCJQ_>3I[HNF"M*
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MMU97E8@QJ*NC-_)&6=XS%'SL[;06V;#4("_D-2IM>8KE3BLU2'4CYS(F#@7
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M#SA#A[..?K#QJRQ)91(-Q(I7!>#DEN(. ;6E"*%7E?*LN+F@27RM"UH(G5J
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M$Q.X^)O'G &7GN,^+>/F$.8CZ/A7#HVZ:G%KG=G(JY9C.O1>RZS-H&PPE44
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ML&N<'2Z UK]O)RI1Z_M>*H=! =5%O.Y^/4>69PQ/R5Q[+MY\$5$S *:]$*E
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MRT7;9^YC#MI5\N[V^4SMF<I 3 V\  0[ZWNMEJZ2V>/- $AP&DQSCDN%LO\
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M[1)1=PJ/B^[B;R,HT4'H/VKM,>@!ULVKII&\-L5E;+ 9=:%P@P8F8 3&!X"
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M(ZC+@?.2L4DVOFD5V#E1T]<>$I?.\64#YU#;CG-U$1'5<4=94/K9(> -3PT
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M]V0+RO[&F*</V-CS(-]#,9TQ9>60%+1M63FF$'C6T;C3E9>0DG2*0( 8PLP
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M$7R8'+5N82J&$:% =6!OVXT]QNU*)+FNA+A@<(Q/%5[Z>6^;26:K+@1^(#\
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MS4KL_9_]S_IZ4UF\PT2]7A][^=&'[NGCUIOLT(3=.C/^3&&?W]7R7))3=_\
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DRA3[7]KZMWE_;^FOI_B_#0A<LOTE[?2'T_3V]/PT(5VA"__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
